Section 3 of 6
Product information and disease description
406 evidence topics · 220 sources
Product description
Phase of product development
Regulatory status: Submission planned; NDA planned for the fourth quarter of 2026
Launch
No evidence found.
NDA submission planned for the second half of 2026, January 2026, superseded in May 2026
First statement of an NDA submission in the fourth quarter of 2026, May 2026
Development history: first phase 2 and phase 3 dosing milestones
Development history: ONWARD enrollment in March 2025 and completion of enrollment in August 2025
Development history: ONWARD1 and ONWARD2 topline results, January 2026
Development history: AAD 2026 late-breaking presentation of ONWARD1 and ONWARD2, March 2026
Development history: ONWARD3 topline results, August 2026
Development history: Fall Clinical Dermatology Conference presentation of ONWARD1, ONWARD2, and ONWARD3, October 2026
ONWARD1 and ONWARD2 topline data expected in the first half of 2026, November 2024, superseded in March 2025
ONWARD1 and ONWARD2 topline data expected in the first quarter of 2026, March 2025, superseded in May 2025
ONWARD1 and ONWARD2 topline data expected early in the first quarter of 2026, May 2025, superseded in January 2026
Phase 2 two-year safety data planned for the fourth quarter of 2026
Phase 2 two-year safety data planned for the second half of 2026, March 2026, superseded in November 2026
Going concern disclosure and cash runway statement, November 2026
Liquidity sufficient for at least 12 months, August 2026, superseded in November 2026
Financing: January 2026 public offering
Financing: at-the-market sales agreement of March 2026
Patent protection: composition of matter, crystalline and salt forms, and methods of treatment
Cumulative clinical exposure: more than 2,000 participants
Japan dermatology rights licensed to Kaken Pharmaceutical, March 2025
LUMUS phase 2b trial in systemic lupus erythematosus: topline results, September 2026
Product information
Generic, brand name and therapeutic class of product
Nonproprietary name, former development code, and therapeutic class
Substance names and development codes in the FDA substance registration record
| Field | Quoted record |
|---|---|
| Preferred substance name | “ENVUDEUCITINIB” |
| International Nonproprietary Name synonym | “envudeucitinib [INN]” |
| Development code synonym | “ESK-001” |
| Second development code synonym | “FTP-637” |
| Systematic chemical name synonym | “N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)-2-pyridinyl]cyclopropanecarboxamide” |
Development code FTP-637 in the first-in-human registry record
Company names and acquisition of envudeucitinib
Dosage forms and strengths
Film-coated immediate-release tablet containing 20 mg
Immediate-release tablet as the current formulation
Replacement of the liquid formulation by a tablet formulation
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Pharmacologic class stated by the manufacturer
Proposed International Nonproprietary Name and class description
| Field | Quoted record |
|---|---|
| Proposed INN (Latin) | “envudeucitinibum” |
| Class description | “Janus kinase inhibitor, anti-inflammatory” |
| Class description (French) | “inhibiteur de la kinase de Janus, anti-inflammatoire” |
Nonproprietary name stem -citinib
Nomenclature and drug dictionary entries in the FDA substance registration record
| Field | Quoted record |
|---|---|
| Substance type | “INGREDIENT SUBSTANCE” |
| Molecular formula | “C22H24N6O3” |
| United States Adopted Name synonym | “ENVUDEUCITINIB [USAN]” |
| WHO Drug Dictionary synonym | “ESK 001 [WHO-DD]” |
Indication
Indication proposed for the planned NDA
Pharmacology
Mechanism of action
Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain
“In contrast, allosteric TYK2 inhibitors such as envudeucitinib achieve selectivity by binding to the pseudokinase JAK homology 2 (JH2) domain, a regulatory site unique to TYK2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This binding induces a conformational change that prevents the activation of the catalytic JH1 domain, thereby functionally blocking ATP binding and TYK2 signaling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the TYK2 JH2 domain is structurally distinct from the JH2 domains of other JAK family members, this allosteric mechanism (indirect inhibition) confers high selectivity for TYK2, preserving JAK 1/2/3 activity and reducing the risk of adverse events associated with classic JAK inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESK‐001 is a highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which plays an essential role in mediating cytokine signaling in multiple immune‐mediated diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, we describe ESK‐001, an orally available and highly selective allosteric TYK2 inhibitor binding to the JH2 domain of TYK2, which is being developed for the treatment of plaque psoriasis, SLE, and other immune‐mediated diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine pathways mediated by TYK2
“TYK2 mediates downstream signaling of IL-23 as well as other cytokines, including IL-12 and type I interferons (IFNs)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, inhibition of TYK2 provides comprehensive targeting that reduces both the signaling and production of the proinflammatory cytokines central to psoriasis pathogenesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inhibition of TYK2 reduces production and inflammatory signaling of cytokines associated with psoriasis without affecting cytokines involved in immune pathways, lipid metabolism, and blood cell development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selectivity for TYK2 over JAK1, JAK2, and JAK3
“Preclinical studies showed that ESK‐001 was pharmacologically active and highly selective against TYK2 (50% inhibitory concentration [IC50] of 104–149 nM in human whole blood), and had no off‐target effects on other kinases (IC50 of >30,000 nM for JAK1‐3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kinome selectivity and binding to the JH2 allosteric pocket
Pharmacodynamics
Maximal TYK2 inhibition over 24 hours with twice-daily dosing
“Indeed, preclinical and phase 1 studies demonstrated that envudeucitinib twice daily achieves maximal TYK2 target inhibition (90% inhibitory concentration [IC90]) at clinically relevant doses over 24 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical inhibition of STAT phosphorylation and interferon-gamma production
“Additionally, ESK‐001 significantly inhibited STAT phosphorylation and downstream IFNγ production stimulated by IL‐12, IL‐23, and IFNα in human whole blood and peripheral blood mononuclear cells in a concentration‐dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood biomarkers of TYK2 inhibition in healthy participants
“ESK‐001 inhibited the downstream TYK2 pathway as shown by inhibition of pSTAT1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transcriptomic analysis of unstimulated whole blood samples confirmed dose‐dependent inhibition of Type I IFN‐induced genes and SIGLEC1, a novel TYK2‐responsive biomarker.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By correlating PK exposure data with PD readouts, a strong PK/PD relationship was demonstrated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood and skin biomarkers in the STRIDE phase 2 study
Circulating IL-23, IL-17A, and IL-22 in the STRIDE phase 2 study
Skin tape-strip transcriptomics and proteomics in a STRIDE subgroup
Spatial transcriptomics of skin biopsies in a STRIDE subgroup
Trough coverage of the IC90 and exposure-response in the STRIDE open-label extension
Interferon-pathway target engagement in the LUMUS phase 2b lupus trial
Cardiac repolarization: structural hypothesis
Pharmacokinetics
Absorption, dose proportionality, accumulation, and steady state in healthy participants
“ESK‐001 was rapidly absorbed with systemic exposures generally increasing dose‐proportionally across all cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half‐life ranged from 8 to 13 h with no to minimal accumulation of ESK‐001 following q.d. doses and ~2‐fold accumulation following Q12 doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following both single (≤100 mg) and multiple (≤60 mg q.d. and ≤40 mg Q12) dose administration, ESK‐001 was rapidly absorbed into the systemic circulation and afterward eliminated in an approximately monoexponential manner with less than 1% renal excretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The systemic exposure of ESK‐001 showed linear dose‐dependent PK characteristics across the dose range, with steady state achieved by 3–5 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physicochemical properties, permeability, and tissue distribution
“ESK‐001 was designed to deliver best‐in‐class pharmacokinetics (PK), including rapid absorption, low PK variability, high permeability with no efflux, and good penetration into relevant tissues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Molecular weight <500 g/mol.” (opens the source at this quote in a new tab)
“Low polar surface area.” (opens the source at this quote in a new tab)
Elimination half-life as stated by the manufacturer and a narrative review
“Envudeucitinib demonstrated a favorable pharmacokinetic profile characterized by rapid absorption, an elimination half-life of approximately 8 h, a dose-proportional increase in exposure, minimal renal clearance, and low interindividual variability” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic clearance, metabolites, and deuteration
“Envudeucitinib is primarily cleared through hepatic metabolism” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies evaluating absorption, distribution, metabolism, and excretion of envudeucitinib in healthy volunteers identified one major and seven minor metabolites (data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major metabolite is pharmacologically inactive with no significant off-target effects; minor metabolites contribute minimally to the overall pharmacologic activity of envudeucitinib (data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Envudeucitinib includes a deuterated methyl triazole moiety that may enhance its metabolic stability by reducing cytochrome P450 1A2 (CYP1A2)-mediated demethylation, mitigating potential metabolite-driven off-target effects, and maximizing the pharmacodynamic response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Peak and steady-state trough concentrations in the STRIDE open-label extension
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Females and males of reproductive potential: contraception requirements in the STRIDE protocol
Drug/Drug, drug/disease interactions
Effects of other drugs on Envudeucitinib
Overall drug interaction potential from in vitro and clinical studies
Effects of Envudeucitinib on other drugs
Drug interaction potential stated by the manufacturer for combination therapy
Phase 1 interaction study with metformin and paroxetine: research ethics committee record
| Field | Quoted record |
|---|---|
| Study title | “Phase 1 Study on impact of ESK-001 PK on Metformin and Paroxetine in Healthy Participants” |
| IRAS ID | “1012125” |
| REC name | “North East - York Research Ethics Committee” |
| REC reference | “25/NE/0105” |
| Date of REC Opinion | “14 Jul 2025” |
| REC opinion | “Further Information Favourable Opinion” |
| Research summary | “Publication of this data is currently deferred.” |
Dosing and administration
Dosage
Selection of 40 mg twice daily for the phase 3 trials
Once-daily modified-release formulation in development to replace twice-daily dosing
Administration
Access and distribution
Launch preparation and commercial infrastructure
Commercialization plans in the United States, the European Union, and Asia-Pacific
Contract manufacturing, redundant supply chain, and distribution of investigational product
Distribution agreements and logistics required after approval
Expanded access policy
Co-prescribed/Concomitant therapies
Prohibited treatments and washout periods in the STRIDE protocol
Duration of the medication restrictions and recording of concomitant medications in the STRIDE protocol
Acid-reducing agents and antiviral medications in the STRIDE protocol
Permitted vaccinations and dietary restrictions in the STRIDE protocol
Discontinuation of study drug for new chronic psoriasis medication in the STRIDE protocol
Effect of Envudeucitinib on quality measures
MIPS Quality ID 410: description, measure type, and denominator
| Field | Specification text |
|---|---|
| Measure type | “Intermediate Outcome – High Priority” |
| Telehealth | “TELEHEALTH ELIGIBLE: This measure is appropriate for and applicable to the telehealth setting.” |
MIPS Quality ID 410: numerator benchmarks for PGA, BSA, PASI, and DLQI
MIPS Quality ID 410: six-month treatment period and denominator exception
MIPS Quality ID 410: reference list of systemic medications, oral agents
| Brand name | Chemical name | Mechanism of action or type of systemic | Indication |
|---|---|---|---|
| Sotyktu | “deucravacitinib” | “Inhibits tyrosine kinase 2 (TYK2)” | “Psoriasis” |
| Otezla | “apremilast” | “Blocks phosphodiesterase-4” | “Psoriasis, Psoriatic arthritis” |
| Neoral | “cyclosporine, modified” | “Blocks lymphocytes (T cells) and lymphokines” | “Psoriasis” |
| Jylamvo | “methotrexate” | “Inhibits dihydrofolic acid reductase” | “Psoriasis” |
| Soriatane | “acitretin” | “Unknown; activates retinoid receptors” | “Psoriasis” |
MIPS Quality ID 410: rationale and clinical recommendation statements on treatment goals
MIPS Quality ID 485: description, measure type, denominator, and numerator for itch severity
MIPS Quality ID 485: rationale on pruritus in psoriasis
QCDR measure AAD15: appropriate assessment and treatment of severe psoriasis
QCDR measure AAD8: patient-reported quality of life in chronic skin conditions including psoriasis
HEDIS and NCQA measures for psoriasis
No evidence found.
Product-specific effect of envudeucitinib on quality measure performance
No evidence found.
Product comparison
Manufacturer statement of competitive factors and comparator classes
Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels
| Feature | Deucravacitinib label text |
|---|---|
| Dosage form and strength | “SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration.” |
| Accumulation with once-daily dosing | “The accumulation of deucravacitinib was <1.4-fold following once daily dosing in healthy subjects.” |
| Tablet handling | “Do not crush, cut, or chew the tablets.” |
| Food | “No clinically significant differences in the pharmacokinetics of deucravacitinib were observed following administration of a high-fat, high-calorie meal” |
| Feature | Apremilast label text |
|---|---|
| Dosage forms and strengths, immediate release | “OTEZLA (apremilast) tablets are supplied in 10 mg, 20 mg, and 30 mg strengths for oral administration.” |
| Dosage form and strength, extended release | “OTEZLA XR (apremilast) extended-release tablets are supplied in a 75 mg strength for oral administration.” |
| Switching between twice-daily and once-daily formulations | “Patients treated with OTEZLA 30 mg twice daily may be switched to OTEZLA XR 75 mg once daily the day following the last dose of OTEZLA 30 mg.” |
| Food | “Administer OTEZLA/OTEZLA XR with or without food.” |
| Tablet handling | “Swallow tablets whole. Do not crush, split, or chew.” |
Elimination half-life, steady state, and metabolism: deucravacitinib, apremilast, and icotrokinra labels
| Parameter | Deucravacitinib label text |
|---|---|
| Half-life | “The terminal half-life of deucravacitinib was 10 hours.” |
| Active metabolite | “The active deucravacitinib metabolite, BMT-153261, has comparable potency to the parent drug” |
| Metabolic pathways | “Deucravacitinib is also metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT) 1A9.” |
Contraindications and hypersensitivity: deucravacitinib, apremilast, and icotrokinra labels
| Feature | Deucravacitinib label text |
|---|---|
| Contraindication | “SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU” |
| Hypersensitivity | “Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving SOTYKTU.” |
| Feature | Icotrokinra label text |
|---|---|
| Contraindications | “None.” |
Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels
| Requirement | Icotrokinra label text |
|---|---|
| Infection risk | “Medicines that interact with the immune system may increase the risk of infection.” |
| Active infection | “Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated.” |
| Tuberculosis monitoring | “Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment.” |
| Active tuberculosis | “Avoid administering ICOTYDE to patients with active TB.” |
| Immunizations before treatment | “Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.” |
| Vaccine response | “No data are available on the response to live or inactive vaccines.” |
Pretreatment screening requirements of deucravacitinib and apremilast
“Before initiating treatment, patients should be screened for tuberculosis (TB) and viral hepatitis, which is not required, for example, before starting apremilast” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels
| Monitoring item | Icotrokinra label text |
|---|---|
| Reduced renal function | “Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min” |
| Anti-drug antibodies | “In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies.” |
| Neutralizing antibodies | “No neutralizing antibodies were detected.” |
Drug interactions: deucravacitinib, apremilast, and icotrokinra labels
| Interaction | Apremilast label text |
|---|---|
| Strong CYP450 inducers | “Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR” |
| Interaction | Icotrokinra label text |
|---|---|
| Clinical interaction studies | “No formal drug-drug interaction studies have been conducted with icotrokinra. No clinically significant drug interactions have been identified.” |
| Cytochrome P450 enzymes | “Icotrokinra does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.” |
Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels
Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels
| Impairment | Apremilast label text |
|---|---|
| Severe renal, immediate release | “In adult patients with severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily.” |
| Severe renal, extended release | “OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage for these patients has not been determined” |
| Hepatic, population studied | “Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment.” |
| Hepatic, dosage | “No dosage adjustment is necessary in these patients.” |
Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors
“Orthosteric inhibitors with activity against TYK2 (e.g., brepocitinib and ropsacitinib) bind the JAK homology 1 (JH1) domain and compete with the natural substrate, ATP, to occupy the active site” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, deucravacitinib has an 87-fold greater biochemical selectivity for the TYK2/JH2 domain compared to the JAK1/JH2 domain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In fact, there is no measurable inhibition of JAK1, JAK2, or JAK3 by envudeucitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Envudeucitinib has a molecular structure that separates it from other TYK2 inhibitors, with a modified arrangement and strategic deuteration sites that contribute to its metabolic stability and pharmacodynamic properties.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zasocitinib is an allosteric TYK2 inhibitor with a mechanism of action analogous to that of deucravacitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It has been bioengineered to demonstrate enhanced selectivity for the TYK2 JH2 domain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors
“In preclinical and phase 1 studies, oral administration of envudeucitinib twice daily achieved maximal (90% inhibitory concentration [IC90]) TYK2 inhibition over 24 h, highlighting a level of sustained target engagement that distinguishes envudeucitinib from other oral immunomodulators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It also exhibits >24 hours of steady state time above IC50 and IC90, indicating prolonged and consistent TYK2 targeting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews
“When compared with apremilast, deucravacitinib exhibits improved tolerability, with fewer discontinuations due to adverse events, as well as greater efficacy, with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) response rates of approximately 55% vs. 37% at week 16” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the efficacy of deucravacitinib is lower than that of most injectable IL-23 or IL-17 inhibitors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given its mechanism of action, deucravacitinib causes less modification of cytokine signaling vs other JAK inhibitors, resulting in a narrower adverse effect (AE) profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is the only JAK or TYK2 inhibitor indicated for psoriasis that does not have a boxed warning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib versus apremilast at week 24 as summarized in a review
Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16
“IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One potential limitation is that this study employs an open-label design rather than a double-blinded design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison: deucravacitinib versus adalimumab through week 112
“Before reweighting, on average, patients in the POETYK PSO-LTE (N = 329) versus the REVEAL (N = 345) extension were older, had a lower body weight, received more prior systemic treatments, and had higher baseline PASI scores and week 16 placebo PASI 75 and PASI 90 response rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following reweighting, adjusted week 112 PASI 75 response rates were significantly higher for deucravacitinib versus adalimumab (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib had a numerically higher adjusted week 112 PASI 90 response rate (41.3% vs. 34.0%; mean difference [95% CI], 7.3 [−2.0 to 16.7] percentage points).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatments had similar week 52 adjusted PASI 75 and PASI 90 response rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by Bristol Myers Squibb.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analyses of TYK2 inhibitors and other oral agents
“In total, 13 RCTs (five for TYK2 inhibitors and eight for PDE4 inhibitors) involving 5274 patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, deucravacitinib (3 mg BID, 6 mg QD, 6 mg BID, and 12 mg QD), and ropsacitinib (400 mg QD) showed superior efficacy than apremilast (30 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of safety, deucravacitinib or ropsacitinib at any dose did not lead to a higher incidence of AEs than apremilast (30 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12- 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tofacitinib (10 mg BID) was considered the most unsafe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study included 66 trials of 27,074 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer cross-trial comparison: PASI 100 with envudeucitinib, icotrokinra, and zasocitinib
Manufacturer cross-trial comparison: itch improvement of at least 4 points on the PSSD at weeks 2, 4, and 16
Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib
“Additionally, direct (e.g., head-to-head) and formal indirect (e.g., meta-analyses) comparisons of oral agents for the treatment of psoriasis are not presently available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By achieving full target engagement without compromising safety, envudeucitinib may offer efficacy comparable to biologics (e.g., IL-23 and IL-17 inhibitors) in an oral formulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medical writing assistance was funded by Alumis Inc. The journal’s Rapid Service Fee was funded by Alumis Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, comparisons between studies are limited as varying methodologies were used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As more TYK2 inhibitors, such as zasocitinib and envudeucitinib, emerge, additional studies will be essential to delineate differences in efficacy, safety, and long-term outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition: chronic immune-mediated skin disease with distinct subtypes
Definition: chronic papulosquamous disease presenting at any age
Case definition in the Global Burden of Disease Study 2021
“In the GBD 2021, psoriasis was defined as a common, chronic, and recurrent inflammatory skin disease characterized by abnormal epidermal keratinization and hyperproliferation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis diagnosis was based on the international Classification of diseases 10 (ICD-10: L40 and L41).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plaque psoriasis as the most common variant
Etiology of chronic plaque psoriasis: HLA-C risk allele and environmental triggers
“Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heritability: population-based twin study of 10,725 twin pairs
“Data on psoriasis in 10 725 twin pairs, aged 20-71 years, from the Danish Twin Registry was collected via a questionnaire survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic factors explained 68% (60-75%) of the variation in the susceptibility to psoriasis, whereas the rest of the variation was explained by nonshared environmental factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heritability range and susceptibility loci from genome-wide association studies
“This was demonstrated by twin, family-based and large-scale population-level studies, with heritability estimated to be 60–90%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than 60 susceptibility loci have now been identified using genome-wide association studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many of the candidate causal genes are involved in antigen presentation (HLA-C and ERAP1), NF-kappa B signalling (TNIP1), type 1 interferon pathway (RNF113 and IFIH1), interleukin (IL)-23/Th17 axis (IL23R, IL12B and TYK2) and skin barrier function (LCE3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Major histocompatibility complex share of detectable heritability
Environmental triggers: obesity, stress, medications, and smoking
Body mass index as a causal risk factor: mendelian randomization
“Overall, a 1 kg/m2 increase in BMI was associated with 4% higher odds of psoriasis (meta-analysis odds ratio [OR] = 1.04; 95% CI 1.03–1.04;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MR analyses provided evidence that higher BMI causally increases the odds of psoriasis (by 9% per 1 unit increase in BMI; OR = 1.09 (1.06–1.12) per 1 kg/m2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Moderate-to-severe plaque psoriasis
Incidence of psoriasis in a retrospective cohort, electronic health records 2014 to 2018
“Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence appears to be stable within a recent 5-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of psoriasis by age, sex, and race
“Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Overall incidence and incidence trend, 1970 to 1999
“The overall age and sex adjusted annual incidence of psoriasis was 78.9 per 100,000 (95% confidence interval [CI]: 75.0, 82.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence of psoriasis increased significantly over time from 50.8 in 1970–74 to reach 100.5 per 100,000 in 1995–1999 time period (p=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall age-adjusted incidence in males (85.5 per 100,000; 95% CI: 79.5, 91.6) was higher than in females (73.2 per 100,000; 95% CI: 68.0, 78.4; p=0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Range of adult incidence across countries: systematic review
“In adults, the incidence of psoriasis varied from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1) in Taiwan to 321.0 per 100 000 person years in Italy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 23 studies that reported on the incidence of psoriasis in the general population were conducted mainly in western and eastern Europe (16 studies), and North America (six studies).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global and high-income North America incidence, Global Burden of Disease Study 2021
| Location | ASIR in 1990 (per 100,000) | ASIR in 2021 (per 100,000) | Cases in 2021 |
|---|---|---|---|
| Global | “57.0(55.3–58.8)”View highlighted excerpt for this quote | “62.0(60.1–63.9)”View highlighted excerpt for this quote | “5,099,418.3 (4,945,748.1–5,254,031)”View highlighted excerpt for this quote |
| High-income North America | “96.5 (93.6–99.4)”View highlighted excerpt for this quote | “103.5 (100.8–106.1)”View highlighted excerpt for this quote | “422,371.3 (410,310.8–434,102.1)”View highlighted excerpt for this quote |
Global incident cases and trend, Global Burden of Disease Study 2021
“In 2021, the global burden of psoriasis remained severe with a total incidence of 5.10 million cases (95% CI: 4.95~5.25 million), representing a 78.76% increase since 1990.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was projected to increase from about 5.10 million cases in 2021 to 8.25 million cases in 2036, an increase of about 61.74%, indicating that the number of people with psoriasis has increased by at least twofold in the last 15 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age-standardized incidence trend, Global Burden of Disease Study 2019
“From 1990 to 2019, the global ASR significantly increased for RA (AAPC = 0.21), albeit the ASRs significantly decreased for AD (AAPC = −0.15), asthma (AAPC = −0.41), MS (AAPC = −0.26), psoriasis (AAPC = −0.77), IBD (AAPC = −0.32).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ASR of psoriasis unanimously decreased among the 21 regions, with the highest decrement observed in North Africa and the Middle East (AAPC = −0.90).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Moderate-to-severe plaque psoriasis
Prevalence in U.S. adults: National Health Interview Survey 2023
Prevalence in U.S. adults by sex, race and ethnicity, and body mass index, 2023
Prevalence in U.S. adults 20 years or older
“Psoriasis prevalence among US adults 20 years or older was 3.0% (95% CI, 2.6%-3.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the 2020 census data, psoriasis affects approximately 7.55 million US adults aged 20 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence in U.S. adults by race and ethnicity and over time, NHANES
“Overall, White individuals reported the highest prevalence of psoriasis at 3.6% (95% CI, 2.9%-4.2%). The lowest psoriasis prevalence was found in Black individuals, with a prevalence of 1.5% (95% CI, 1.0%-2.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of psoriasis among those aged 20 to 59 years within the 2011-2014 NHANES data was 2.9% (95% CI, 2.5%-3.4%). This most recent prevalence estimate was not statistically different from prevalence estimates from prior years of 2.9% (95% CI, 2.3%-3.5%) during the 2009-2010 NHANES cycle and 3.2% (95% CI, 2.2%-4.5%) from the 2003-2004 NHANES cycle (P = .84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence trend in U.S. adults: NHANES and NHIS, 2003 to 2024
“Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total sample included 53,225 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No temporal trends in prevalence were found in any sociodemographic subgroup.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosed and undiagnosed psoriasis in U.S. adults
“The prevalence of diagnosed psoriasis was 3.15% (95% CI 2.18, 4.53), corresponding to 5 million adults. The prevalence of undiagnosed active psoriasis by conservative estimate was 0.4% (95% CI 0.19, 0.82) corresponding to approximately 600,000 US adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Moderate-to-severe fraction: three or more palms of body surface area
“In this study, we found that 21.5% of participants reported having moderate to severe psoriasis (≥3 palms of body surface area involvement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients with psoriasis reported having little or no psoriasis at the time of the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reported severity: no or little, mild, and moderate or severe disease
“Psoriasis severity was generally mild: 54.5% (95% CI=44.8, 63.9) reported no or little disease; 27.3% (95% CI=21.1, 34.6) reported mild disease; and 18.2% (95% CI=12.4, 25.9) reported moderate or severe disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Moderate-to-severe fraction and number affected, ages 20 to 59
| Body surface area category | Proportion of psoriasis patients |
|---|---|
| Little or no psoriasis | “51.59%”View highlighted excerpt for this quote |
| 1% to 2% | “31.68%”View highlighted excerpt for this quote |
| 3% to 10% | “11.38%”View highlighted excerpt for this quote |
| More than 10% | “5.25%”View highlighted excerpt for this quote |
“83.37% of psoriasis patients with a history of physician diagnosis had mild psoriasis (little/no to 1–2% BSA) while 16.63% had moderate to severe disease (3% or greater BSA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, we estimate that 1.4 million patients age 20–59 have moderate to severe disease and that 2.1 million consider psoriasis to be a large problem in daily life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psoriasis prevalence and severity distribution in the adult population
“The median prevalence of psoriasis in the adult population using the Bayesian estimate was 3.0% (95% credibility interval, 2.7–3.3%), compared with the estimated mean prevalence of 3.4% (95% confidence interval, 2.2–4.9%). By EE, the estimated cumulative distribution of disease severity assessed by BSA suggests that approximately 50% of patients have a BSA of < 3% and 78% of patients have a BSA of < 10%, with only 2% having a BSA of > 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on EE, approximately 22% of the adult population with psoriasis has 10% or more of BSA involved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insured U.S. population with moderate-to-severe psoriasis and untreated share
“There were an estimated 1.7 million insured US patients with moderate to severe psoriasis. Of these, 1 million (59%) were not treated for their condition in the preceding year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assigning disease severity by treatment types, excluding patients with mild disease (4,065,721) and those prescribed treatment for a related inflammatory comorbidity (191,753), resulted in an estimated 1,700,266 insured patients with moderate to severe psoriasis in the 5-year analysis window (Fig. 4). Of these, 546,814 (32.2%) were diagnosed but not treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment types received by insured U.S. patients with moderate-to-severe psoriasis
“Furthermore, of the patients treated (lapsed + currently treated) in the prior year, 156,409 (22.5%), 222,657 (32.0%), 22,911 (3.3%), and 293,511 (42.2%) received a biologic, traditional oral systemic, phototherapy, or a topical treatment, respectively (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, this large health-plan-claims-based study showed that 40.9% of 1.7 million eligible US patients were receiving therapy for moderate to severe psoriasis in the 12 months up to September 2012.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Claims-based prevalence and severity distribution
“Based on several psoriasis identification algorithms, the claims-based prevalence for psoriasis in the United States ranged from 0.51% to 1.23%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using this method, 70.9% of patients had mild disease and 27.3% had moderate to severe disease (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Therapies received in the claims analysis
“Most patients had at least one claim for psoriasis therapy (83.5%), and 16.5% received no therapy. Topical therapies were used by 76.6% (N=3,551), the majority of whom received topical corticosteroids (97.9%). Phototherapy was used by 7% (N=324). Oral systemic medications were used by 14.3% (N=664), the majority of whom received methotrexate (85.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence, severity at its worst, and undertreatment
“The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regional prevalence, including high income North America
“The prevalence of psoriasis varied from 0.14% (95% uncertainty interval 0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other regions with an occurrence of the disease above 1% were western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), high income North America (1.50%, 0.63% to 3.60%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalent cases, Global Burden of Disease Study 2021
“In 2021, the global prevalence number of people with psoriasis reached 42.98 million cases (95% CI: 41.65~44.31 million), representing an increase of approximately 86.4% compared to the number of cases in 1990.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide number of people with psoriasis
Natural history, survival, and mortality
Lifelong course with associated morbidity
No cure: management aims
“Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age at onset: bimodal distribution
“Findings revealed consistency across studies about the bimodal age pattern of the onset of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When we examined the incidence of psoriasis by sex and age bands, the two peaks for age at onset in women were more frequently around 18-29 and 50-59 years, whereas in men they occurred more frequently around 30-39 and 60-69 or 70-79 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis, 1970 to 1999
“The mean age at diagnosis (± standard deviation) of psoriasis was 43.2 ± 17.0 years and 828 (51.0%) subjects were male (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Average age at incidence increased across the three decades from 39.8 years in 1970–1979, to 41.9 years in 1980–1989 and 45.5 years in 1990–1999 (p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression between clinical forms and erythroderma
“Patients with guttate psoriasis may later develop plaque psoriasis. In rare cases of severe uncontrolled disease, psoriasis causes a widespread erythematous rash (erythroderma) that is life-threatening due to potential complications including hypothermia, risk of infection, acute kidney injury and high-output cardiac failure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality and life expectancy in severe psoriasis
“There was no overall effect of mild psoriasis on mortality (HR, 1.0; 95% confidence interval [CI], 0.97-1.02), whereas patients with severe psoriasis demonstrated an increased overall mortality risk (HR, 1.5; 95% CI, 1.3-1.7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Male and female patients with severe psoriasis died 3.5 (95% CI, 1.2-5.8) and 4.4 (95% CI, 2.2-6.6) years younger, respectively, than patients without psoriasis (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cause-specific mortality and age at death in severe psoriasis
“Patients with severe psoriasis were at increased risk of death from cardiovascular disease (HR 1.57; 95%CI 1.26–1.96), malignancies (HR 1.41; 95%CI 1.07–1.86), chronic lower respiratory disease (HR 2.08; 95%CI 1.24–3.48), diabetes (HR 2.86; 95%CI 1.08–7.59), dementia (HR 3.64; 95%CI 1.36–9.72), infection (HR 1.65; 95%CI 1.26–2.18), kidney disease (HR 4.37; 95%CI 2.24–8.53), and unknown/missing causes (HR 1.44; 95%CI 1.09–1.88).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, psoriasis patients died at a younger age than unexposed patients (mean age of 73 vs 79 years respectively, p<0.001), as shown graphically in Figure 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular mortality in severe psoriasis
“Severe psoriasis was an independent risk factor for CV mortality (HR 1.57; 95% CI 1.26, 1.96) when adjusting for age, sex, smoking, diabetes, hypertension, and hyperlipidaemia. Overall, severe psoriasis patients experienced one extra CV death per 283 patients per year, even when adjusting for major CV risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, the RR of CV death for a 40-year-old and 60-year-old with severe psoriasis was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and cardiovascular mortality by severity: meta-analysis of 12 studies
“We included 12 studies. The pooled RRs for all-cause mortality were 1.21 (95% CI 1.14-1.28) in psoriasis, 1.13 (95% CI 1.09-1.16) in mild psoriasis, and 1.52 (95% CI 1.35-1.71) in severe psoriasis. The pooled RRs for cardiovascular mortality were 1.15 (95% CI 1.09-1.21) in psoriasis, 1.05 (95% CI 0.92-1.20) in mild psoriasis, and 1.38 (95% CI 1.09-1.74) in severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For noncardiovascular causes, mortality risk from liver disease, kidney disease, and infection was significantly increased in psoriasis, regardless of disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality over a median follow-up of 52.3 months
“Over an average median follow-up of 52.3 months, psoriasis was significantly associated with increased mortality risk (HR, 1.99; 95% CI, 1.01-3.93; P = .047) with adjustment for demographics, smoking, and comorbidities including cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancer, chronic kidney disease, and stroke.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival compared with the Minnesota white population
“Survival in the overall psoriasis cohort was similar to that expected in the Minnesota white population (standardized mortality ratio [SMR]: 0.95, 95% CI: 0.84, 1.07, p=0.36) over the entire time period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
IL-23/IL-17 axis as the central immune pathway
“Over the last two decades, research has unequivocally shown that psoriasis represents a bona fide T-cell mediated disease primarily driven by pathogenic T-cells that produce high levels of IL-17 in response to IL-23.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriatic disease is, therefore, best understood as a patterned response to chronic activation of the IL-23/T17 pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IL-17 and IL-23 as key drivers identified by immunological and genetic studies
Interplay of T cells, dendritic cells, and keratinocytes
“This suggests a complex interplay between T cells, dendritic cells and keratinocytes as the likely underlying the pathophysiology of psoriasis, with the IL-23/Th17 axis being the central driver of immune activation, chronic inflammation and keratinocyte proliferation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Keratinocyte responses to IL-17: epidermal hyperplasia and leukocyte recruitment
“Epidermal hyperplasia, a hallmark of psoriatic plaques, is associated with STAT3 activation and indirectly regulated by IL-17 through the induction of IL-19 and/or IL-36 by keratinocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IL-17 induces keratinocytes to synthesize and release CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 (i.e. IL-8), which leads to the recruitment of neutrophils and macrophages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TYK2 signaling downstream of IL-12, IL-23, and type I interferon receptors
“Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tyrosine kinase 2 (TYK2) is a member of the JAK family of kinases and regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TYK2 partner kinases and STAT proteins by cytokine
“TYK2 pairs with JAK2 and engages mainly STAT4 to mediate signal transduction of IL-12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TYK2/JAK2 heterodimer, acting through STAT1, STAT3, and STAT4, is likewise required for IL-23 signalling, which regulates the differentiation and survival of Th17 cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss-of-function TYK2 variant P1104A: protection against psoriasis and other autoimmune diseases
“Rs34536443 leads to the substitution of a highly conserved proline residue with an alanine at position 1104 (P1104A) in the kinase domain of the TYK2 protein” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the rs34536443 minor allele is protective across all of the diseases tested, and surprisingly, its dosage effect shows a previously unrecognized significant departure from additivity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This arises from minor allele homozygosity at the rs34536443 SNP, which drives a near complete loss of TYK2 function and consequently impairs type I IFN, IL-12 and IL-23 signaling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Clinical diagnosis with biopsy in doubtful cases
Clinical assessment: body surface area, PASI, PGA, and DLQI
“Psoriasis is assessed by the extent of skin involvement (body surface area (BSA)) and the severity of erythema, induration and scaling. In secondary care, validated scores such as Psoriasis Area Severity Index (PASI) and Physician Global Assessment Scale are routinely used along with patient reported outcome measures such as Dermatology Life Quality Index (DLQI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Measures of disease activity: PASI, PGA, body surface area, and DLQI
“Although it has its drawbacks, the most established parameter to measure the severity of skin symptoms in patients with psoriasis is the Psoriasis Area and Severity Index (PASI), which was first introduced in 1978 as an outcome measure in a retinoid trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A physician global assessment (PGA) score to evaluate disease severity can be beneficial in daily clinical care in order to rapidly assess the severity of psoriasis. It is important to note that different PGAs exist and that they may differ in the way they are defined and scales that are used. An estimate of the percentage of the affected body surface area (BSA) is also used as a means to measure disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“So far, the Dermatology Life Quality Index (DLQI) has been the most commonly used score for assessing the impact of psoriasis on HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body surface area estimated by palm count
Limitations of PASI and other clinical severity measures: systematic review of 53 measures
“The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reliability of PASI, body surface area, and PGA
“In all 3 scales the ICCs were > 0.75, indicating high intra-rater reliability. The highest ICC was for the BSA (0.96) and the lowest one for the PGA (0.87). The CV for the PGA and PASI were 29.3 and 36.9, respectively, indicating moderate inter-rater variability. The CV for the BSA was 57.1, indicating high inter-rater variability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Five-point Investigator's Global Assessment scale
“The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dermatology Life Quality Index score bands
“DLQI scores 0-1 = no effect on patient's life (GQ = 0, n = 754); DLQI scores 2-5 = small effect on patient's life (GQ = 1, n = 611); DLQI scores 6-10 = moderate effect on patient's life (GQ = 2, n = 327); DLQI scores 11-20 = very large effect on patient's life (GQ = 3, n = 242); DLQI scores 21-30 = extremely large effect on patient's life (GQ = 4, n = 59)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity classification: mild and moderate-to-severe definitions with upgrade criteria
“Currently, the disease definition most commonly used for psoriasis is strongly influenced by the definition used in clinical trials. It was thoroughly discussed and formally agreed upon in a European consensus project in 2011.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity classification: topical or systemic candidacy
“This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Skin lesions: well-demarcated plaques with silvery-white scale on extensor surfaces, trunk, and scalp
“The most common form is plaque psoriasis, which presents as well-demarcated salmon pink plaques with silvery-white scale, typically in a symmetrical distribution and affecting the extensor surfaces (especially elbows and knees), trunk and scalp (Fig 1). Bleeding points may be noted where scales have been removed (Auspitz sign).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Koebner phenomenon describes the appearance of psoriasis at skin areas affected by trauma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skin symptoms: itching, redness, flaking, and scales in patient survey
“Patients commonly reported PsO involvement in special areas, and more than half of patients had scalp involvement (Table 2). Most patients reported PsO symptoms; itching, redness, flaking, and scales occurred in ~ 90% of patients or more (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pruritus: lifetime and point prevalence
“Pruritus ever in the course of psoriasis (the lifetime prevalence of pruritus) was experienced by the great majority (92.9%) of patients, while 81% reported the presence of this symptom within the 3 days preceding the examination (the point prevalence of pruritus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nail involvement: pitting, onycholysis, and dystrophy
“Nails may be affected in up to 50% of patients and may manifest as nail pitting (indentation in the nails), onycholysis (separation of nail plate from nail bed), oil spots (discoloration of the nailbed), dystrophy and subungual hyperkeratosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nail involvement: prevalence and associated severity in 3,531 patients
“Nail psoriasis was diagnosed in 40·9% of the patients; prevalence was 11·2 percentage points higher in men than in women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with nail involvement had a longer disease duration (21·9 vs. 18·1 years), higher disease severity (mean Psoriasis Area and Severity Index 12·7 vs. 9·3), higher frequency of PsA (26·0% vs. 12·7%), stronger impairment of HRQoL (mean Dermatology Life Quality Index 8·9 vs. 7·3), and a 2·5-fold higher rate of inpatient treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genital involvement: prevalence, itch, pain, and dyspareunia
“One hundred thirty-four patients (38%) had current genital involvement while 224 (63%) had a current and/or previous history of genital involvement. Eighty-seven percent reported itch, 39% pain, 42% dyspareunia, 32% a worsening of their genital psoriasis after intercourse, and 43% a decreased frequency of intercourse.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
High-impact sites: scalp, face, nails, genitalia, palms, and soles
Musculoskeletal symptoms: joint discomfort in patients with psoriasis alone
“Among patients with PsO alone (n = 2550), 58% reported experiencing joint discomfort; of these (n = 1485), 63% had ≤ 4 involved joints (consistent with oligoarthritis). When asked if they have experienced PsA symptoms, many patients with PsO alone reported morning stiffness of the joints (44%), nail involvement (32%), pain and/or swelling of the feet (24%), or” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Psoriatic arthritis: incidence and risk factors in a prospective cohort
“The data obtained from the 464 patients who were followed up for 8 years were analyzed. A total of 51 patients developed PsA during the 8 years since enrollment. The annual incidence rate of PsA was 2.7 cases (95% confidence interval 2.1-3.6) per 100 psoriasis patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A severe psoriasis phenotype, presence of nail pitting, low level of education, and uveitis are predictive of the development of PsA in patients with psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psoriatic arthritis: pooled prevalence, 266 studies
“A total of 266 studies examining 976,408 patients with psoriasis were included. Overall, the pooled proportion (95% confidence interval [CI]) of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The PsA prevalence was 22.7% (95% CI, 20.6%-25.0%) in European patients with psoriasis, 21.5% (95% CI, 15.4%-28.2%) in South American patients with psoriasis, 19.5% (95% CI, 17.1%-22.1%) in North American patients with psoriasis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of PsA among patients with psoriasis ranged from 0.27 to 2.7 per 100 person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psoriatic arthritis: onset after skin disease
Myocardial infarction risk by severity and age
“The incidences per 1000 person-years for control patients and patients with mild and severe psoriasis were 3.58 (95% confidence interval [CI], 3.52-3.65), 4.04 (95% CI, 3.88-4.21), and 5.13 (95% CI, 4.22-6.17), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For example, for a 30-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.29 (95% CI, 1.14-1.46) and 3.10 (95% CI, 1.98-4.86), respectively. For a 60-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.08 (95% CI, 1.03-1.13) and 1.36 (95% CI, 1.13-1.64), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Major adverse cardiovascular events: meta-analysis of nine studies
“Severe psoriasis was associated with a significantly increased risk of cardiovascular mortality (RR, 1.39; 95% CI, 1.11 to 1.74), myocardial infarction (RR, 1.70; 95% CI, 1.32 to 2.18), and stroke (RR, 1.56 95% CI, 1.32 to 1.84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on these risk ratios and the background population event rates, psoriasis is associated with an estimated excess of 11 500 (95% CI, 1169 to 24 407) major adverse cardiovascular events each year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diabetes: prevalence and incidence meta-analysis
“Among studies assessing the prevalence, psoriasis was associated with an odds ratio (OR) of 1.59 (95% CI, 1.38-1.83) for diabetes. The pooled OR was 1.53 (95% CI, 1.16-2.04) for mild psoriasis and 1.97 (1.48-2.62) for severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among studies that assessed incidence, psoriasis was associated with a relative risk of 1.27 (95% CI, 1.16-1.40) for developing diabetes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome: pooled odds ratio and dose-response relationship
“Based on random-effects modeling of cross-sectional and case-controlled studies, the pooled odds ratio (OR) for metabolic syndrome among patients with psoriasis was 2.26 (95% confidence interval [CI] 1.70-3.01) compared with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A dose-response relationship was also observed between psoriasis severity and prevalence of metabolic syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-alcoholic fatty liver disease: meta-analysis in chronic plaque psoriasis
“We identified 15 observational (case–control and cross-sectional) studies for a total of 249,933 patients with psoriasis (49% with NAFLD) and 1,491,402 controls (36% with NAFLD). Psoriasis was associated with prevalent NAFLD (n = 11 studies; pooled random-effects odds ratio [OR] 1.96, 95% CI 1.70–2.26; I2 = 97%, p < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inflammatory bowel disease: meta-analysis
“Significant associations were found between psoriasis and Crohn disease (odds ratio, 1.70; 95% CI, 1.20-2.40) and between psoriasis and ulcerative colitis (odds ratio, 1.75; 95% CI, 1.49-2.05). Patients with psoriasis had an increased risk of Crohn disease (risk ratio, 2.53; 95% CI, 1.65-3.89) and ulcerative colitis (risk ratio, 1.71; 95% CI, 1.55-1.89).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression: prevalence and odds meta-analysis
“The prevalence of depressive symptoms was 28% using questionnaires and the prevalence of clinical depression was 12% using International Classification of Diseases codes, 19% using Diagnostic and Statistical Manual of Mental Disorders IV, and 9% for antidepressant use.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis patients had significantly more depressive symptoms (SMD 1.16; 95% confidence interval (CI) 0.67-1.66), and population-based studies showed that they were at least one and a half times more likely to experience depression (OR 1.57; 95% CI 1.40-1.76) and used more antidepressants than did controls (OR 4.24, 95% CI 1.53-11.76).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidities in moderate-to-severe psoriasis compared with matched controls
“A total of 5,492 matched pairs of moderate-to-severe PsO patients and controls were selected, with a mean age of 47.6 years and 55.5% of patients being male.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PsA was present among 22.1% of PsO patients. Excluding PsA, the most common comorbidities in PsO patients were related to metabolic syndrome, including hyperlipidemia (33.3% vs. 27.3%, adjusted OR [aOR] = 1.3), hypertension (32.8% vs. 23.5%, aOR = 1.6), and diabetes (15.8% vs. 9.7%, aOR = 1.7). Obesity, another condition related to metabolic syndrome, was observed in 4.8% of PsO patients, compared with 2.3% of controls (aOR = 1.9). Depression and anxiety affected 9.1% and 6.3% PsO patients, respectively (aOR = 1.7 and 1.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, PsO patients had an elevated risk of coronary heart disease (aOR = 1.5), cerebrovascular disease (aOR = 1.7), peripheral vascular disease (aOR = 1.6), skin cancer (aOR = 1.9) including nonmelanoma skin cancer (aOR = 2.1), and lymphoma (aOR = 22.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic comorbidity rising with severity
“Individuals with psoriasis are more likely to suffer from obesity, cardiovascular disease, non-alcoholic fatty liver disease, diabetes and metabolic syndrome than the general population, with rates being especially elevated in those with more severe psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psoriatic arthritis: prevalence of 30% to 33% and onset 10 to 11 years after psoriasis
Psoriatic arthritis: prevalence by psoriasis duration and odds by body surface area involvement
Coronary artery calcification in moderate-to-severe psoriasis
Stroke: adjusted hazard ratios and excess risk by severity
Metabolic syndrome: prevalence in a practice-matched cohort
Hypertension and diabetes: prevalence in a German health insurance database
Dyslipidemia: hazard and odds ratios compared with controls
Depression: likelihood compared with controls
Crohn disease and ulcerative colitis: prevalence compared with matched controls
Malignancy: nonmelanoma skin cancer, lymphoma, and other cancers
Chronic kidney disease: adjusted hazard ratios by severity
Obstructive sleep apnea and chronic obstructive pulmonary disease
Nonalcoholic fatty liver disease: prevalence on liver ultrasound
Comorbidity guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation
Burden of Moderate-to-severe plaque psoriasis
Humanistic burden and health-related quality of life
Dermatology Life Quality Index overall and by body surface area: UPLIFT survey in North America, Europe, and Japan
“UPLIFT was a large, online, population-based survey conducted in North America, Europe, and Japan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, in patients with PsO and/or PsA (n = 3614), mean DLQI score was 9.3, and 56% of patients experienced at least a moderate impact on QOL (DLQI score > 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with PsO and/or PsA with limited BSA (≤ 3 palms; n = 2497), 56% had DLQI score > 5; 80% of patients with moderate BSA (4–10 palms) and 88% of patients with large BSA (> 10 palms) had DLQI total score > 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dermatology Life Quality Index with special-area involvement and limited body surface area: UPLIFT survey
“In patients with PsO involvement in at least one special area (n = 2776), the mean (SD) DLQI total score was 9.9 (8.5) and 57.9% reported DLQI total score > 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In UPLIFT, 60% of PsO patients with limited BSA and involvement (BSA ≤ 3 palms) in at least one special area (n = 1927) reported their current disease as moderate or severe. Of these, 51% were receiving topical treatment or no treatment. In this group of patients, mean DLQI score was 9.4, and more than half of patients (56.4%) had a DLQI score > 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positive depression screen and quality of life impairment in survey respondents with psoriasis or psoriatic arthritis
“Approximately half of patients (52%) with PsO and/or PsA (n = 3806) screened positive for potential major depressive disorder, according to PHQ-2 guidelines (i.e., PHQ-2 score ≥ 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with DLQI total score > 5 and PsO in at least one special area who also had PHQ-2 score ≥ 3 had higher mean (SD) DLQI total scores [16.8 (6.7); n = 1203] compared with all patients with DLQI total score > 5 and PsO in at least one special area [15.5 (6.85); n = 1607, without positive depression screen].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy
“The Corrona Psoriasis Registry is an independent, prospective observational cohort launched in April 2015 in collaboration with the National Psoriasis Foundation, with a target enrolment of 10 000 patients with psoriasis from 200 sites throughout the USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As of 31 May 2016, 1529 patients were enrolled in the registry; the mean age was 50.6 years and 47% were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BSA percentages were categorised as mild (0%–5%), moderate (>5%–10%), severe (>10%–15%) and very severe (>15%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across BSA categories, mean fatigue scores ranged from 26.5 to 40.2, itching was 24.7 to 55.7 and pain was 15.2 to 41.7. Among IGA categories, mean fatigue scores ranged from 21.9 to 41.8, itching was 12.1 to 57.3 and pain was 7.4 to 44.3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across BSA and IGA categories, mean DLQI scores ranged from 5.2 to 10.2 and 4.3 to 9.7, respectively. Mean EQ-VAS scores ranged from 62.9 (very severe) to 76.4 (mild) across BSA categories and 62.1 (severe) to 78.8 (clear/almost clear) across IGA categories, with higher scores indicating better health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall DLQI and EQ-VAS scores also worsened with disease severity (p<0.05 for each level of BSA and IGA) (table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D and Dermatology Life Quality Index differences by severity: U.S. survey of 694 patients
“During a recent US survey, dermatologists provided information on overall disease severity, symptom severity and comorbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study analysed 694 patients (55% male; mean age: 44 years); 48%, 46% and 6% had mild, moderate and severe psoriasis, respectively. Scaling was the most common symptom, which was experienced by 82% of patients, followed by itching (73%) and pain (32%). Increased psoriasis severity was associated with increased itching, pain and scaling, and with reduced QoL (decrease in EQ-5D scores: moderate vs. mild -0.04, severe vs. mild -0.18; increase in DLQI: moderate vs. mild 2.97, severe vs. mild 7.95).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D health state utility values: meta-analysis of 59 studies
“For meta-analysis, we identified 70 utility scores from 59 studies: 22 for plaque psoriasis, 26 for psoriasis as a general condition, and 22 for psoriatic arthritis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (95% CIs; I2) of the EQ-5D utility scores for psoriasis as a general condition, plaque psoriasis, and psoriatic arthritis was 0.748 (0.718, 0.777; 98.8%), 0.755 (0.727, 0.783; 98.6%), and 0.585 (0.538, 0.632; 98.2%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For psoriasis as a general condition and plaque psoriasis, factors such as country, psoriasis area and severity index (PASI), dermatology life quality index (DLQI) and questionnaire version (EQ-5D-3L or EQ-5D-5L) all significantly influenced the utility scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Emotional wellbeing, embarrassment, concealment, pain, and pruritus: National Psoriasis Foundation surveys, 2003 to 2011
“The National Psoriasis Foundation (NPF) conducts semiannual surveys and collects information regarding comorbid conditions, medication use, treatment patterns, impact on quality of life, and disease burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 2003 to 2011, 5,604 patients completed the surveys. Psoriasis and psoriatic arthritis affected overall emotional wellbeing in 88% of patients, and they interfered with enjoyment of life in 82%. Most patients reported experiencing anger (89%), frustration (89%), helplessness (87%), embarrassment (87%), and self-consciousness (89%). Many patients also actively concealed physical manifestations of their diseases (83%), and experienced pain (83%) and pruritus (93%) regularly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Problem in daily life by self-reported severity: survey of 5,452 respondents
“The patients were asked to assess how much of a problem psoriasis has been in their daily life on a scale of 0–10 (0 = no problem and 10 = a very large problem).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 5452 patients reported a median of 5 (interquartile range 3–7)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among these respondents, patients with mild psoriasis reported a median of 3 (interquartile range 1–6), whereas patients with severe psoriasis reported a median of 7 (interquartile range 4–9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emotional wellbeing, quality of life, self-image, and stigma: U.S. online survey of 793 patients, 2020 to 2021
“In brief, the study was a cross-sectional, quantitative online survey conducted in the USA between 12 November 2020 and 19 May 2021 and comprised a 5-min eligibility screener followed by a 25-min online questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis included 793 US patients with psoriasis; 43% also had PsA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients stated that their skin symptoms made them feel unattractive (42%), less confident about themselves (37%), ashamed of their skin (35%), depressed (33%), or ashamed of their body (30%; Supplementary Material Fig. S5b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many patients also noted that they had experienced stigma and discrimination, such as people not understanding the impact the disease had on the patient’s life (36%), being asked if they were contagious (36%), and being stared at in public (34%) (Supplementary Material Fig. S5a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Negative comments from others in conversations about psoriasis
“The patients reported that, on an average month, their psoriasis came up in conversations with others a mean of 5.8 times (SD±10). Among these conversations on psoriasis, 51% contained negative comments from others regarding the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated negative stereotypes and perceived stigma by patient-reported severity: University of Pennsylvania dermatology clinics, 106 participants
“Patients with psoriasis were recruited from dermatology clinics at the University of Pennsylvania.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients (n = 106) were 48.11% female, 70.75% white, and had a mean age ± SD of 47.90 ± 16.19 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Linear regression analyses demonstrated that patient-reported severe psoriasis, compared to mild psoriasis, was associated with greater anticipation of negative stereotypes, social avoidance, and perceived stigma from others (P values < .05). Physician-measured body surface area and global assessment scores were not significantly associated with any outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety disorders and anxiety symptoms: meta-analysis of 101 studies
“A total of 101 eligible articles were identified. Meta-analysis revealed different prevalence rates depending on the type of anxiety disorder: 15% [95% confidence interval [CI] 9–21] for social anxiety disorder, 11% [9–14] for generalized anxiety disorder, and 9% [95% CI 8–10] for unspecified anxiety disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analysis also showed a high prevalence of anxiety symptoms (34% [95% CI 32–37]). Case-control studies showed a positive association between psoriasis and unspecified anxiety disorder (odds ratio 1.48 [1.18; 1.85]) and between psoriasis and anxiety symptoms (odds ratio 2.51 [2.02; 3.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incident depression, anxiety, and suicidality by severity: UK population-based cohort
“A population-based cohort study using data collected as part of patient's electronic medical record from 1987 to 2002.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical diagnosis of depression, anxiety and suicidality were compared among 146,042 mild psoriasis, 3,956 severe psoriasis, and 766,950 control patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted hazard ratios for receiving a diagnosis of depression, anxiety and suicidality in patients with psoriasis compared to controls, were 1.39 (95% CI 1.37, 1.41), 1.31 (95% CI 1.29, 1.34) and 1.44 (95% CI 1.32, 1.57), respectively. The adjusted relative risk of depression was higher in severe (HR 1.72, 95% CI 1.57, 1.88), compared to mild psoriasis (HR 1.38, 95% CI 1.35, 1.40).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We estimate that in the UK, in excess of 10,400 diagnoses of depression, 7,100 diagnoses of anxiety, and 350 diagnoses of suicidality are attributable to psoriasis annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sleep quality and sleep disturbance: meta-analysis of 15 studies
“Fifteen studies including 1274 patients with psoriasis and 775 controls were analysed. A higher PSQI (weighted mean difference [WMD] = 3.397, P < 0.001, I2 = 84.2%) and a higher risk for SD (odds ratio [OR] = 6.640, P < 0.001, I2 = 67.5%) were observed in patients with psoriasis compared with controls. Subgroup analyses revealed a greater difference in PSQI score and/or risk for SD between patients with psoriasis and controls in subgroups of psoriatic arthritis, moderate-to-severe psoriasis, shorter psoriasis duration, and younger age.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Avoidance of sexual activity because of psoriatic disease
“In terms of relationships, although 32% of patients reported that their partner loved them just the way they were, 21% said that they avoided having sex because of their condition or could not stand the thought of someone touching or seeing their skin (Supplementary Material Fig. S5c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Erectile dysfunction: meta-analysis of eight studies
“Overall, 1829449 participants (the mean age ranged from 44 years to 56.3 years) were included from 8 studies (6 cross-sectional, 1 cohort, and 1 case-control study); 39490 of whom were patients with psoriasis, with the mean disease duration from 6 months to 19.9 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Synthesis results from the included studies revealed that psoriasis was significantly associated with an increased risk of ED in psoriatic patients (OR = 1.62, 95%CI: 1.37-1.91, P < 0.001; heterogeneity: I2 = 62.6%, P = 0.009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Female sexual dysfunction: meta-analysis of eight studies
“Eight studies (five case-control, three cross-sectional) were eligible for review, encompassing 563 women with psoriasis and 525 controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis was associated with greater odds of female sexual dysfunction (OR 2.67, 95% CI 1.93,3.69; p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Total annual U.S. cost of psoriasis in 2013 U.S. dollars: systematic review of 22 studies
“Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual US cost of psoriasis amounted to approximately $112 billion in 2013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual U.S. burden by component: incremental medical costs, quality of life, and productivity, 2013
“The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause costs and resource use in moderate-to-severe psoriasis versus matched controls: OptumHealth claims, 2007 to 2012
“Adults aged 18-64 years with at least 2 PsO diagnoses (ICD-9-CM code 696.1) were identified in the OptumHealth Reporting and Insights claims database from January 2007 to March 2012. Moderate-to-severe PsO patients were identified as those receiving ≥ 1 systemic therapy or phototherapy during the 12-month study period following the index date (randomly selected date after the first PsO diagnosis). Controls were free of PsO and psoriatic arthritis (PsA) and were matched 1:1 with PsO patients on age, gender, and geographic region.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause health care costs and PsO-related costs (PsO treatment costs and PsO-related medical costs, calculated for moderate-to-severe PsO patients only) were calculated as reimbursed amounts from payers and were adjusted to 2012 U.S. dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with controls, PsO patients incurred higher annual total health care costs per patient ($22,713 vs. $4,993, adjusted cost difference [ACD] = $18,960; P < 0.001), driven by significantly higher costs in all-cause medications ($14,698 vs. $1,101, ACD = $13,990; P < 0.001) and all-cause medical services ($8,015 vs. $3,892, ACD = $3,895; P = 0.002; Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the 12-month study period, the moderate-to-severe PsO patients incurred an average of $13,731 PsO-related costs, a majority of which were attributed to treatment costs for systemic PsO therapies ($12,958) that included biologics, nonbiologics, and phototherapies (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, PsO patients were more likely to incur all-cause medical services, including any inpatient admissions (9.3% vs. 6.4%, aOR = 1.3), ER visits (21.4% vs. 16.4%, aOR = 1.3), and outpatient visits (99.0% vs. 84.5%, aOR = 29.3; all P < 0.001). On average, PsO patients had more inpatient admissions (0.15 vs. 0.09, aIRR = 1.3; P = 0.001), ER visits (0.40 vs. 0.27, aIRR = 1.3; P < 0.001), and outpatient visits (20.46 vs. 8.41, aIRR = 2.4; P < 0.001). PsO patients also spent more hospitalization days (1.03 vs. 0.55, aIRR = 1.9; P < 0.001) than controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual all-cause costs in psoriasis versus matched controls: U.S. claims study
“To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare resource utilization and costs (in 2019 USD) were evaluated descriptively and through mixed models for five years of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 142,531 psoriasis and 21,428 PsA patients were matched to the control group (N = 163,959). Annual all-cause healthcare costs per patient were $7,470, $11,062, and $29,742 for the control, psoriasis, and PsA groups, respectively. All-cause healthcare costs increased over time and were significantly greater among PsA vs. psoriasis (p < 0.0001) and the control groups (p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause costs by severity, psoriatic arthritis, and biologic use over five years: MarketScan claims, 2009 to 2014
“Administrative data from Truven Health Analytics MarketScan Research Database were used to select adult patients with psoriasis from January 2009 to January 2014.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are presented per-patient-per-year (PPPY) and by years 1, 2, 3, 4, and 5 of follow-up, expressed in 2014 US dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 108,790 psoriasis patients were selected, with a mean age of 46.0 years (52.7% females). Average follow-up was 962 days. All-cause healthcare costs were $12,523 PPPY. Outpatient pharmacy costs accounted for 38.6% of total costs. All-cause healthcare costs were highest for patients on biologics ($29,832), then for patients with psoriatic arthritis ($23,427) and those with moderate-to-severe disease ($21,481). Overall, all-cause healthcare costs and outpatient pharmacy costs presented an upward trend over a 5-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs and outpatient encounters by severity among biologic-treated patients: linked U.S. claims and electronic health records
“To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study identified 2,130 biologic-treated psoriasis patients: 282 (13%) had mild, 116 (5%) moderate, and 49 (2%) severe disease; 1,683 (79%) could not be classified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to mild psoriasis patients, patients with moderate or severe disease had more median all-cause outpatient encounters (28.0 [mild] vs 32.0 [moderate], 36.0 [severe]), more median psoriasis-related outpatient encounters (6.0 [mild] vs 7.5 [moderate], 8.0 [severe]), and a higher proportion of overall claims for medications that were psoriasis-related (28% [mild] vs 37% [moderate], 34% [severe]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to mild psoriasis patients, patients with moderate or severe disease had higher median all-cause total costs ($37.7k [mild] vs $42.3k [moderate], $49.3k [severe]), higher median psoriasis-related total costs ($32.7k [mild] vs $34.9k [moderate], $40.5k [severe]), higher median all-cause pharmacy costs ($33.9k [mild] vs $36.5k [moderate], $36.4k [severe]), and higher median psoriasis-related pharmacy costs ($32.2k [mild] vs $33.9k [moderate], $35.6k [severe]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Six-month direct and indirect costs in moderate-to-severe plaque psoriasis: nine U.S. sites
“A total of 200 adults seeking MSPP treatment enrolled in 9 US sites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (79.5%) were prescribed 1 or more MSPP medications (mean: 1.5); 36.0% and 9.0% received self-administered biologics and systemic therapies, respectively. Mean number of nonprescription treatments was 12.3. Differences by PASI group were observed for overall work and activity impairment (P < .02). Six-month total MSPP direct costs per patient were $11,291; indirect costs were $2101 and differed across PASI groups (P = .0008).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual medication costs, biologics versus oral systemic therapies, and visit use by severity: U.S. dermatology electronic health records
“Data for adults (≥18-years) with a dermatology provider-given diagnosis of psoriasis from 9/2014–9/2015 were obtained from dermatology practices using a widely used US dermatology-specific EHR containing over 500,000 psoriasis patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 28,754 patients, higher disease severity was associated with increased healthcare resource utilization (increased visit frequency and complexity). When compared between treatment groups (n = 10,454), healthcare resource utilization was highest for phototherapy. Annual medication costs were higher for biologics ($21,977) than oral systemics ($3413).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual net cost of first-line biologics, 2007 to 2021
“Trends in the proportion of patients initiating each biologic medication and the average estimated annual treatment costs over time, using commercial estimates of net prices accounting for average manufacturer rebates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 76 781 patients with plaque psoriasis who initiated biologic medications, 50.4% were female and 49.6% male, 71.8% were age 30 to 59 years, and 30% had concurrent inflammatory arthritis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual treatment cost increased from $21 236 in 2007 to $47 125 in 2021. In 2021, costs ranged from $12 413 (infliximab) to $70 043 (risankizumab). If patients initiated the lowest-cost medication in each class, the average annual treatment cost would have been 44% lower in 2021 ($26 363).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs and resource use by biologic treatment pattern: switchers, discontinuers, and nonswitchers
“Of the 8,710 patients with psoriasis included in the study, 5,000 (57.4%) were categorized as nonswitchers, 1,001 (11.5%) as switchers, and 2,709 (31.1%) as discontinuers. Emergency department and inpatient visits, respectively, were more common among switchers (adjusted incidence rate ratio [95% CI]: 1.10 [0.93-1.30] and 1.13 [0.84-1.53]) and discontinuers (1.50 [1.34-1.63] and 2.05 [1.70-2.48]) than among nonswitchers. Compared with nonswitchers, switchers had higher adjusted mean total health care costs (mean difference [95% CI]: $10,120 [$8,235-$12,033]), which were driven by increased prescription costs ($8,988 [$7,535-$10,610]) and medical costs ($2,746 [$1,090-$4,677]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, the adjusted mean total health care cost for discontinuers was lower than that for nonswitchers (mean difference [95% CI]: -$18,611 [-$20,254, -$17,025]) due to reduced prescription costs (-$20,486 [-$21,319, -$19,636]); however, discontinuers had a higher mean medical cost ($3,729 [$1,970-$5,527]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity-related medical costs in moderate-to-severe psoriasis versus the general population: U.S. claims, 2006 to 2019
“Comorbidity-related HCRU (incidence rate ratios [IRRs]) and direct medical cost burden (per patient per month [PPPM] 2020 USD) in patients with moderate to severe PsO in the USA, previously apremilast- and biologic-naive, but currently treated, versus the general population were assessed through a retrospective cohort study using IBM (now Merative) MarketScan Commercial and Medicare Claims data (1 January 2006 to 31 December 2019).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These differences (PsO–general population) in HCRU and costs (IRR visits; PPPM) are associated with specific comorbidities, including mental health (1.08; $372), chronic pulmonary disease (1.07; $135), diabetes (1.10; $159), hyperlipidemia (1.13; $203), hypertension (1.13; $305), liver disease (1.21; $360), and obesity (1.12; $145, all P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total and work-loss costs by number of psoriasis-related comorbidities: U.S. privately insured patients
“Adults with psoriasis (≥2 diagnoses, the first designated as the index date) and non-psoriasis controls (no psoriasis diagnoses, randomly generated index date) were identified in a US healthcare claims database of privately-insured patients (data between January 2010 and March 2017 were used).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 9,078 psoriasis (mean age = 44 years, 51% female) and 48,704 non-psoriasis (mean age = 41 years, 50% female) patients were selected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis patients incurred greater total healthcare costs (mean cost differences [MCDs] = $1,590, $5,870, and $18,427, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]), and work-loss-related costs (MCDs = $335, $655, and $1,695, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity loss and annual indirect costs by severity: Adelphi survey in the U.S. and five European countries
“To estimate total WPL and related indirect costs, and identify predictors of WPL associated with psoriasis severity in France, Germany, Spain, the U.K. and Italy (EU5) and the U.S.A.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from the 2015 Adelphi Real World Psoriasis Disease Specific Programme, analysed for absenteeism, presenteeism and total WPL, were quantified (0–100%) from participants who completed the Work Productivity and Activity Impairment (WPAI) instrument.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 936 respondents (29·6% U.S.A., 70·4% EU5) who completed the WPAI, 32·6%, 40·7% and 26·6% had mild [body surface area (BSA) 0–2%], moderate (BSA 3–10%) and severe (BSA > 10%) psoriasis, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean percentages of total WPL for respondents with mild, moderate and severe psoriasis were 10·1%, 18·9% and 29·4%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annual indirect costs due to WPL per patient were highest in the U.S.A. (9591 U.S. dollars, 95% CI 8407–10 775), reflecting a particularly high contribution from presenteeism (9173 U.S. dollars, 95% CI 8063–10 283).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment and disability by body surface area category
“By BSA category, the ‘work hours missed’ domain was 2.3%–5.9%, ‘impairment while working’ was 8.4%–19.0%, ‘work hours affected’ was 9.5%–20.0% and ‘daily activities impaired’ was 13.1%–31.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing proportions of patients were disabled as severity increased according to BSA (range: 7%–14%) and IGA (range: 5%–15%; table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment score differences by severity
Unemployment and missed work days among survey respondents
“Of note, 12% of patients were unemployed, and 11% worked part-time. Among unemployed patients, 92% cited psoriasis and/or psoriatic arthritis as the sole reasons for not working. Among working patients, 49% missed work days regularly due to psoriasis. Compared to patients with mild psoriasis, patients with severe psoriasis have 1.8 times greater odds to be unemployed after adjusting for age and gender (Adjusted OR = 1.7, 95% CI 1.4–2.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a typical month, among those who missed work days due to psoriasis or PsA, 62% missed 5 days or less, 6.6% missed 6–10 days, and 31% missed more than 10 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual indirect costs by level of skin clearance: employed participants of the CLEAR trial
“In the CLEAR study, 452 (67%) were employed at baseline and included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“U.S. Department of Labor data were used to calculate annual indirect costs due to work productivity loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Associated mean annual indirect costs due to work productivity loss per worker decreased with higher PASI improvements: $10,318 for PASI < 50, $6,042 for PASI 50-74, $2,901 for PASI 75-89, and $2,233 for PASI ≥ 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inability to work or study and monthly out-of-pocket spending among survey respondents
“Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the highest out-of-pocket costs (mean $240 per month) related to healthcare, prescriptions, doctors’ fees, alternative practitioners, dietitians, and complementary medicine, with nonprescription medicines, creams, and lotions being the next highest cost (mean $147 per month).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Moderate-to-severe plaque psoriasis on families
Extra housework, psychological pressure, and social disruption among 63 relatives and partners
“Thirty-three subjects were interviewed and 30 replied by postal questionnaire. Twenty-eight of the 63 subjects were relatives (seven men and 21 women) and 35 were partners (16 men and 19 women).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seventy per cent stated that the treatment of their relative or partner resulted in them having to spend extra time on housework; 57% described psychological pressures including anxiety, being upset and being worried about the patient's future; 55% described social disruption due to lack of social confidence either because of embarrassment or because of the time required for care duties; 44% described limitations to holiday plans, sport and leisure activities and evenings out; 37% described limitations on their daily activities such as shopping, work and time spent with other family members; 37% felt that their close relationships had deteriorated. Only 8% described no effect at all on their QoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The QoL of the relatives and partners (number of categories affected) was more closely related to the patients' QoL (DLQI: r = 0.77, P < 0.001; PDI: r = 0.67, P < 0.001) than to the objective disease severity scores (PASI: r = 0.34, P < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Partner burden, including cleaning, by psoriasis severity: FamilyPso international study of 556 patients and partners
“A prospective cohort study was conducted in 11 centers in Austria, Canada, Germany, Italy, Spain, and Turkey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cohort consisted of 556 people with psoriasis and their partners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-assessed high severity of psoriasis was a predictor for a higher burden in 4/5 FamilyPso domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest scores were found for the acute/general emotional strain and the cleaning domains (Fig. 3). The partners’ burden increased by severity in each domain. The steepest slopes are found with emotional strain and cleaning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data show that emotional aspects, such as a feeling of helplessness with the chronic illness of the partner, and increased cleaning efforts add to the burden that psoriasis imposes on partners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden on close relatives and partners by severity and patient quality of life: Psoriasis Registry Austria
“250 plaque‐type psoriasis patients (58.4% males and 41.6% females) with mostly treatment‐controlled disease (mean PASI of 1.7 and Dermatology Life Quality Index (DLQI) of 4.1) were recruited from the Psoriasis Registry Austria (PsoRA) and their close relatives and partners were invited to participate in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Valid FamilyPso questionnaires were returned from 153 (61.2%) close relatives and partners. Correlation analysis revealed a significant association between PASI and DLQI (r = 0.512, p < 0.001), PASI and PFIS (r = 0.228, p = 0.006), and DLQI and PFIS (r = 0.210, p = 0.014).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A small or larger disease burden was detected in nearly 78.7% of the male and 77.3% of the female relatives and partners quantified with categorized PFIS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gender of the relatives and partners had no impact on the PFIS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life, anxiety, and depression in cohabitants of patients
“The study included patients, cohabitants, and controls, a total of 130 participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The presence of psoriasis impaired the quality of life of 87.8% of the cohabitants. FDLQI scores of cohabitants were significantly associated with the DLQI scores of the patients (rs = 0.554; P < .001). Anxiety and depression levels did not differ between patients and cohabitants, but were significantly higher than in the controls (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family Dermatology Life Quality Index: instrument for family members of patients with skin disease
“A 10-item questionnaire, the Family Dermatology Life Quality Index (FDLQI), was finalized after modifications to the draft questionnaire based on feedback from families and dermatology professionals and on item reduction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A strong correlation was seen between the family members' FDLQI scores and patients' DLQI scores (r = 0.69), a significantly higher FDLQI score was seen for inflammatory skin diseases compared with noninflammatory diseases/isolated lesions (P < 0.0001), and there was a positive relationship between the family members' FDLQI scores and patients' disease severity (r = 0.49).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lifestyle, emotional, and relationship consequences for family members: focus groups and interviews
“We conducted focus groups and interviews with 23 individuals; 12 had a family member with AD, and 11 had a family member with psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three major themes emerged: (1) lifestyle consequences-many daily activities for family members, including but not limited to leisure activities, sleep, and cleaning, were affected by AD or psoriasis; (2) emotional consequences-family members felt frustrated, worried, or embarrassed, among other concerns, because of their loved ones' AD or psoriasis; (3) relationships-relationships between family members and their loved ones with AD or psoriasis could become strained, and though family members might try to be sympathetic, doing so could be difficult because of their lack of understanding of how these diseases feel and personally affect their loved ones.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family income by psoriasis severity: Polish specialty clinic
“A total of 83 (45 male) psoriasis patients, treated at a Polish specialty clinic, were assessed for their financial and employment status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients' family income correlate negatively with psoriasis severity (Spearman's rho = -0.356; P < 0.01). Disease severity in patients with a family income below the social minimum was significantly higher (PASI: 20.5 ± 12.2) than in patients with a higher family income (PASI: 11.7 ± 7.7, P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Family income was found to link disease severity to global QoL impairment (P < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregivers of children with psoriasis: meta-analysis of 21 studies
“Twenty‐one studies were included, encompassing 1038 children and 1161 caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across studies, 84.8% of children and 96.1% of caregivers experienced some degree of HrQOL impairment. Meta‐analysis revealed a moderate positive correlation between child disease severity (PASI scores) and caregiver HrQOL burden (r = 0.463), while no significant correlation was found with child age or disease duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Topical therapies
Topical corticosteroids: guideline recommendation, potency selection, and efficacy ranges by potency class
Topical corticosteroids: local adverse effects, tachyphylaxis, and duration limits
Topical vitamin D analogues and corticosteroid combinations: guideline recommendations and adverse effects
Topical agents added to systemic therapy in moderate to severe psoriasis: guideline recommendations
Topical agents alone among treated patients with moderate or severe psoriasis
Guideline evidence base for topical and UV therapy statements
Joint AAD-NPF guideline on topical therapy: scope and National Psoriasis Foundation collaboration
Phototherapy
Narrowband UVB: guideline recommendations on monotherapy, dosing frequency, and preference over PUVA
Narrowband UVB efficacy: PASI 75 and clearance rates in pooled trials
Oral PUVA compared with narrowband UVB: efficacy, number of treatments, and adverse effects
Treatment burden: travel to a phototherapy center and home phototherapy
Phototherapy safety precautions: guideline recommendations
Phototherapy use relative to other treatment types
“The most frequently used phototherapy modality is UV-B, whereas methotrexate is the most commonly used oral agent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients lapsed and currently treated in this period, the numbers who received each treatment type were 156,409 (biologic), 222,657 (traditional oral systemic), 22,911 (phototherapy), and 293,511 (topical).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Joint American Academy of Dermatology and National Psoriasis Foundation phototherapy guideline: scope and update of the 2010 guideline
Conventional systemic therapies
Methotrexate: guideline recommendations on use, comparative efficacy, dosage, and folate supplementation
Methotrexate efficacy in randomized trials: PASI 75 versus placebo and adalimumab
Methotrexate oral solution: FDA-approved indication, dosage, boxed warning, and hepatotoxicity in psoriasis
Methotrexate: guideline statements on dose, principal adverse reactions, and myelosuppression
“The recommended initial and maintenance dose is usually 15 mg MTX once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most important adverse drug reactions (ADRs) in association with MTX therapy are mucositis, MTX‐induced pneumonitis, hepatotoxicity, and myelosuppression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another rare, but serious adverse event of MTX therapy is myelosuppression with an estimated prevalence of <1% (7/100,000 patient years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cyclosporine: guideline recommendations and PASI response rates
Cyclosporine: FDA-approved indication, dosage, and boxed warning for psoriasis
Cyclosporine nephropathy and malignancies in psoriasis
Acitretin: guideline recommendation and PASI 75 response
Acitretin: FDA-approved indication, dosage, and pregnancy warning
Network meta-analysis: methotrexate and ciclosporin compared with biologics, apremilast, and placebo
“Infliximab, adalimumab, ixekizumab, and risankizumab were more effective than methotrexate (infliximab: RR 2.86, 95% CI 2.15 to 3.80; adalimumab: RR 3.73, 95% CI 2.25 to 6.19; ixekizumab: RR 2.05, 95% CI 1.43 to 2.94; risankizumab: RR 2.37, 95% CI 1.59 to 3.54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a lower risk of SAEs for participants on methotrexate compared to placebo (RR 0.15, 95% CI 0.03 to 0.72).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our confidence in the results for non‐targeted systemic treatments is limited due to concerns regarding study conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic nonbiologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation
PDE4 inhibitors
FDA-approved indication, dosage, and titration: apremilast
Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label
| Endpoint at Week 16, n (%) | PSOR-1 placebo (N = 282) | PSOR-1 OTEZLA 30 mg BID (N = 562) | PSOR-2 placebo (N = 137) | PSOR-2 OTEZLA 30 mg BID (N = 274) |
|---|---|---|---|---|
| PASI-75 | “15 (5.3)” | “186 (33.1)” | “8 (5.8)” | “79 (28.8)” |
| sPGA of clear or almost clear | “11 (3.9)” | “122 (21.7)” | “6 (4.4)” | “56 (20.4)” |
ESTEEM 1: PASI-75 at week 16, maintenance through week 52, and adverse events
“ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P < .0001; primary end point).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most (61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7% rerandomized to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the placebo-controlled period, 55.7% and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESTEEM 2: PASI 75, PASI 50, and sPGA 0 or 1 at week 16 and common adverse events
“ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The modified intention-to-treat population (full analysis set) included 137 placebo and 274 apremilast patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more apremilast patients achieved PASI 75 (28·8%), PASI 50 (55·5%) and static Physician's Global Assessment score of 0 or 1 (20·4%) vs. placebo (5·8%, 19·7%, 4·4%, respectively; P < 0·001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were nausea, diarrhoea, nasopharyngitis and upper respiratory tract infection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label
| Adverse reaction, n (%) | Placebo (N = 506) | OTEZLA 30 mg BID (N = 920) |
|---|---|---|
| Diarrhea | “32 (6)” | “160 (17)” |
| Nausea | “35 (7)” | “155 (17)” |
| Tension headache | “21 (4)” | “75 (8)” |
| Headache | “19 (4)” | “55 (6)” |
Discontinuation, depression, and weight decrease: apremilast label
Apremilast: guideline recommendation, gastrointestinal adverse effects, and absence of laboratory monitoring
Network meta-analysis: phosphodiesterase-4 inhibitors, serious adverse events and PASI 75 compared with biologics
“Phosphodiesterase‐4 inhibitors had the highest SUCRA at class level in terms of SAEs (versus placebo: RR 0.76, 95% CI 0.47 to 1.23; SUCRA = 70.8)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a difference in favour of infliximab, anti‐IL17 agents (ixekizumab, bimekizumab, and secukinumab), and risankizumab compared to ustekinumab, other anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and synthetic targeted treatments (apremilast and deucravacitinib) in terms of achieving PASI 75.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: estimated PASI response rates at 10 to 16 weeks for apremilast and dimethyl fumarate
Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks
“A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The long-term PASI rates were estimated via a traditional meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case analysis included all biologics, apremilast, and dimethyl fumarate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TYK2 inhibitors
FDA-approved indication, dosage, and pretreatment tuberculosis evaluation: deucravacitinib
Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label
| Endpoint, n (%) | SOTYKTU (N=330) | Placebo (N=166) | Apremilast (N=168) |
|---|---|---|---|
| sPGA 0/1, Week 16 | “178 (54)” | “12 (7)” | “54 (32)” |
| PASI 75, Week 16 | “193 (58)” | “21 (13)” | “59 (35)” |
| PASI 90, Week 16 | “118 (36)” | “7 (4)” | “33 (20)” |
| Endpoint at Week 24, Trial PSO-1, n (%) | SOTYKTU (N=330) | Apremilast (N=168) |
|---|---|---|
| PASI 75 | “228 (69)” | “64 (38)” |
| PASI 90 | “140 (42)” | “37 (22)” |
POETYK PSO-1: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast
“Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
POETYK PSO-2: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast
“POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more deucravacitinib-treated patients versus placebo and apremilast patients achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and static Physician's Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001 for both).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent adverse event with deucravacitinib was nasopharyngitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events and discontinuations due to adverse events were infrequent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Randomized withdrawal: maintenance of sPGA 0 or 1 at week 52 with continued deucravacitinib versus placebo
Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label
| Adverse reaction, n (%) | SOTYKTU 6 mg once daily (N=840) | Placebo (N=419) |
|---|---|---|
| Upper respiratory infections | “161 (19.2)” | “62 (14.8)” |
| Blood creatine phosphokinase increased | “23 (2.7)” | “5 (1.2)” |
| Herpes simplex | “17 (2)” | “1 (0.2)” |
| Mouth ulcers | “16 (1.9)” | “0 (0.0)” |
| Folliculitis | “14 (1.7)” | “0 (0.0)” |
Warnings: infections, creatine phosphokinase elevation, triglycerides, and potential JAK inhibition risks
Continuous deucravacitinib: PASI 90 and DLQI 0/1 through 4 years
“In patients who received continuous deucravacitinib (n = 513), clinical and patient‐reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucravacitinib exposure-adjusted safety through 5 years
“Overall, 1519 patients received one or more deucravacitinib dose; total exposure was 5046.7 PY through data cutoff (September 2, 2024).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EAIRs/100 PY were comparable or decreased from the 1-year to 5-year cumulative period for adverse events (AEs) (229.23, 127.40, respectively), serious AEs (5.68, 5.06), discontinuation due to AEs (4.38, 2.09), deaths (0.20, 0.22), serious infections excluding coronavirus disease 2019 (COVID-19) (1.53, 0.94), malignancies (1.02, 0.92), major adverse cardiovascular events (0.30, 0.34), and venous thromboembolism (0.20, 0.06).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies
“Deucravacitinib may increase the risk of infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the pivotal trials POETYK PSO‐1, PSO‐2 and the open‐label extension study, ten of the 18 patients reporting herpes zoster were less than 50 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled data from clinical trials on changes in laboratory findings show that treatment with deucravacitinib may result in the following changes in laboratory findings: increase of creatine kinase (from asymptomatic to rhabdomyolysis), increase of triglyceride levels and increase of liver enzymes by ≥ 3‐fold of the upper limit of normal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the pooled data from the complete treatment periods of the pivotal trials PSO‐1, PSO‐2, and the open‐label extension study (overall, 2,482 patient‐years of exposure with deucravacitinib), malignancies were reported in 22 patients (0.9 per 100 patient‐years), including eleven cases of non‐melanoma skin cancer (0.4 per 100 patient‐years) and three cases of lymphoma (0.1 per 100 patient‐years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: deucravacitinib compared with biologics and apremilast for PASI 90
“There was evidence of a difference in favour of infliximab, anti‐IL17 agents (bimekizumab, ixekizumab, secukinumab, sonelokimab, brodalumab), and anti‐IL23 agents (risankizumab and guselkumab) compared to ustekinumab, tildrakizumab, the three anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and deucravacitinib in terms of achieving PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib and risankizumab were more effective than apremilast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib: phase 2b dose-ranging trial, PASI 75 at week 12
“Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib: LATITUDE PsO 3001 and 3002 week 16 results versus placebo and apremilast
| Endpoint at Week 16 | LATITUDE PsO 3001 | LATITUDE PsO 3002 |
|---|---|---|
| sPGA 0/1 | “71% zasocitinib vs 11% placebo and 32% apremilast (p<0.001)” | “69% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)” |
| PASI 75 | “76% zasocitinib vs 12% placebo and 37% apremilast (p<0.001)” | “71% zasocitinib vs 12% placebo and 33% apremilast (p<0.001)” |
Zasocitinib versus deucravacitinib: LATITUDE Atlas week 16 results
Zasocitinib: NDA accepted under Priority Review, PDUFA target in the first quarter of 2027
Oral IL-23 receptor antagonist peptides
FDA approval year, indication, dosage, and administration: icotrokinra
Trial PSO-1 efficacy versus placebo and deucravacitinib: icotrokinra label
| Endpoint, Trial PSO-1, n (%) | ICOTYDE (N=311) | Placebo (N=156) | Deucravacitinib (N=307) |
|---|---|---|---|
| IGA 0 or 1 with ≥2-grade improvement, Week 16 | “213 (68)” | “17 (11)” | “154 (50)” |
| PASI 75, Week 16 | “231 (74)” | “18 (12)” | “176 (57)” |
| PASI 90, Week 16 | “171 (55)” | “6 (4)” | “91 (30)” |
| PASI 100, Week 16 | “97 (31)” | “2 (1)” | “34 (11)” |
| Endpoint at Week 24, Trial PSO-1, n (%) | ICOTYDE (N=311) | Deucravacitinib (N=307) |
|---|---|---|
| IGA 0 or 1 with ≥2-grade improvement | “230 (74)” | “161 (52)” |
| PASI 90 | “205 (66)” | “127 (41)” |
Trial PSO-2 efficacy versus placebo and deucravacitinib: icotrokinra label
| Endpoint, Trial PSO-2, n (%) | ICOTYDE (N=320) | Placebo (N=81) | Deucravacitinib (N=322) |
|---|---|---|---|
| IGA 0 or 1 with ≥2-grade improvement, Week 16 | “227 (71)” | “7 (9)” | “177 (55)” |
| PASI 90, Week 16 | “184 (58)” | “1 (1)” | “111 (34)” |
| Endpoint at Week 24, Trial PSO-2, n (%) | ICOTYDE (N=320) | Deucravacitinib (N=322) |
|---|---|---|
| PASI 90 | “208 (65)” | “141 (44)” |
ICONIC-ADVANCE 1 and 2: icotrokinra versus placebo and deucravacitinib, week 16 and week 24
“Participants (ADVANCE 1: 774 of 988 patients screened; ADVANCE 2: 731 of 917 patients screened) were randomly assigned to icotrokinra (n=311 and 322), placebo (n=156 and 82), or deucravacitinib (n=307 and 327).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Higher proportions of icotrokinra-treated versus placebo-treated participants achieved IGA 0 or 1 (ADVANCE 1: 213 [68%] of 311 vs 17 [11%] of 156, treatment difference 95% CI 58% [50-64]; ADVANCE 2: 227 [70%] of 322 vs seven [9%] of 82, 62% [53-69]; both p<0·0001) and PASI 90 (ADVANCE 1: 171 [55%] of 311 vs six [4%] of 156, treatment difference 95% CI 51% [44-57]; ADVANCE 2: 184 [57%] of 322 vs one [1%] of 82, 56% [48-62]; both p<0·0001) at week 16.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To week 24, adverse event rates were lower than with icotrokinra (359 [57%] of 632) than deucravacitinib (411 [65%] of 634).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Icotrokinra showed superior clinical response rates versus placebo and deucravacitinib in phase 3 moderate-to-severe plaque psoriasis trials, with similar adverse event rates to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ICONIC-ADVANCE 1 and 2 through week 52: durability of skin clearance
“ICONIC-ADVANCE 1 and 2 randomized 1505 participants (774 and 731, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Skin clearance rates among participants randomized to icotrokinra increased through week 24 and were durable through week 52, with approximately 70-75% exhibiting clear/almost clear skin (IGA 0/1, PASI 90) and approximately 50% demonstrating completely clear skin (IGA 0, PASI 100) during weeks 24-52.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who transitioned from placebo or deucravacitinib to icotrokinra exhibited increasing response rates that were comparable to participants randomized to icotrokinra through week 52.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ICONIC-LEAD: icotrokinra versus placebo in adults and adolescents, week 16
“Participants were assigned in a 2:1 ratio to receive icotrokinra at a dose of 200 mg once daily through week 24 or placebo through week 16 followed by transition to icotrokinra.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response, and 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Complete clearance of skin at week 16 was significantly more likely with icotrokinra than with placebo (IGA score of 0, 33% vs. 1%; PASI 100 response [100% reduction from baseline in the PASI score], 27% vs. <1%; P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants with at least one adverse event through week 16 was 49% in each group; the most common adverse events in each group were nasopharyngitis and upper respiratory tract infection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Icotrokinra in psoriasis involving high-impact sites, week 16
“The proportions of participants achieving an IGA score of 0 or 1 in the icotrokinra and placebo groups were 56.7% and 5.8%, respectively [adjusted difference, 51.1 percentage points; 95% confidence interval (CI), 42.1 to 58.8; P<0.001].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportions of icotrokinra-treated and placebo-treated participants achieving absence/clear or minimal/almost clear high-impact site psoriasis were as follows: scalp, 65.9% and 10.6% (difference, 55.5 percentage points; 95% CI, 44.8 to 64.4; P<0.001); genitalia, 76.5% and 21.4% (difference, 55.4 percentage points; 95% CI, 39.1 to 68.0; P<0.001); and hand and foot, 41.7% and 26.1% (difference, 16.7 percentage points; 95% CI, -6.2 to 36.8; P=0.144).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions through week 16 and warnings: icotrokinra label
| Adverse reaction, n (%) | ICOTYDE (N=1296) | Placebo (N=568) |
|---|---|---|
| Headache | “51 (4.1)” | “19 (3.3)” |
| Nausea | “15 (1.2)” | “3 (0.5)” |
| Cough | “15 (1.2)” | “1 (0.2)” |
| Fungal infection | “14 (1.1)” | “0 (0)” |
Pooled safety of icotrokinra through 1 year and versus deucravacitinib through week 24
“Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TNF inhibitors
Biologics guideline: recommendations for etanercept, infliximab, and adalimumab
Adalimumab: FDA-approved indication, dosage, and boxed warning
Adalimumab: Study Ps-I efficacy at week 16 and maintenance through week 52
| Endpoint at Week 16, n (%) | HUMIRA 40 mg every other week (N = 814) | Placebo (N = 398) |
|---|---|---|
| PGA clear or minimal | “506 (62%)” | “17 (4%)” |
| PASI 75 | “578 (71%)” | “26 (7%)” |
Etanercept: FDA-approved indication, dosage, boxed warning, and Study II efficacy at 3 months
“Starting Dose: 50 mg twice weekly for 3 months” (opens the source at this quote in a new tab)
“Maintenance Dose: 50 mg once weekly” (opens the source at this quote in a new tab)
| Outcome at 3 months, Study II, n (%) | Placebo (N = 204) | Etanercept 25 mg BIW (N = 204) | Etanercept 50 mg BIW (N = 203) |
|---|---|---|---|
| PASI 75 | “6 (3%)” | “66 (32%)” | “94 (46%)” |
| sPGA clear or minimal | “7 (3%)” | “75 (37%)” | “109 (54%)” |
Infliximab: FDA-approved indication, intravenous dosage, boxed warning, and week 10 PASI 75
| PASI 75 at Week 10, n (%) | Placebo | REMICADE 3 mg/kg | REMICADE 5 mg/kg |
|---|---|---|---|
| Psoriasis Study II (EXPRESS II) | “4 (2%)” | “220 (70%)” | “237 (75%)” |
| Psoriasis Study III (SPIRIT) | “3 (6%)” | “71 (72%)” | “87 (88%)” |
Certolizumab pegol: FDA-approved indication, dosage, and boxed warning
Decision aid: TNF inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Adalimumab | “31%” | “74–76% chance” |
| Certolizumab pegol | “24%” | “Not known at present” |
| Etanercept | “18%” | “67–73% chance” |
| Infliximab | “91%” | “54–74% chance” |
Network meta-analysis: infliximab and other TNF inhibitors
“At drug‐level, using SUCRA, infliximab had a better chance of reaching PASI 90 (versus placebo: RR 49.99, 95% CI 20.83 to 119.95; SUCRA = 91.8; moderate‐certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was also evidence of a higher risk of SAEs for participants on infliximab compared to methotrexate (RR 2.41, 95% CI 1.04 to 5.59).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guselkumab, risankizumab, ixekizumab and bimekizumab were more effective than adalimumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab, secukinumab, infliximab, ixekizumab, and tildrakizumab were more effective than etanercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Infliximab, 5 mg/kg | “80.4 (76.5-84.0)”View highlighted excerpt for this quote | “57.4 (52.2-62.8)”View highlighted excerpt for this quote | “26.5 (22.3-31.4)”View highlighted excerpt for this quote |
| Certolizumab pegol, 400 mg | “71.1 (65.4-76.5)”View highlighted excerpt for this quote | “45.6 (39.3-52.2)”View highlighted excerpt for this quote | “17.7 (13.8-22.3)”View highlighted excerpt for this quote |
| Adalimumab, 40 mg | “69.5 (66.0-72.6)”View highlighted excerpt for this quote | “43.7 (40.0-47.4)”View highlighted excerpt for this quote | “16.5 (14.2-19.0)”View highlighted excerpt for this quote |
| Etanercept, 25 mg twice weekly/50 mg once weekly | “40.1 (35.4-45.1)”View highlighted excerpt for this quote | “17.9 (14.9-21.4)”View highlighted excerpt for this quote | “4.2 (3.1-5.4)”View highlighted excerpt for this quote |
Biologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation
Decision aid columns: PASI 90 in the first 6 months from network meta-analyses and staying on treatment for more than 1 year from UK real-world data
IL-12/23 inhibitors
Biologics guideline: ustekinumab recommendation
Ustekinumab: FDA-approved indication and weight-based dosage every 12 weeks
Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12
| Outcome at Week 12, n (%) | Ps STUDY 1 placebo (N=255) | Ps STUDY 1 STELARA 45 mg (N=255) | Ps STUDY 1 STELARA 90 mg (N=256) | Ps STUDY 2 placebo (N=410) | Ps STUDY 2 STELARA 45 mg (N=409) | Ps STUDY 2 STELARA 90 mg (N=411) |
|---|---|---|---|---|---|---|
| PASI 75 response | “8 (3%)” | “171 (67%)” | “170 (66%)” | “15 (4%)” | “273 (67%)” | “311 (76%)” |
| PGA of cleared or minimal | “10 (4%)” | “151 (59%)” | “156 (61%)” | “18 (4%)” | “277 (68%)” | “300 (73%)” |
Decision aid: ustekinumab
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Ustekinumab | “34%” | “84–86% chance” |
Network meta-analysis: ustekinumab compared with other biologics and oral agents
“Anti‐IL17 class had a better chance of reaching PASI 90 using SUCRA (versus placebo: RR 25.58, 95% CI 21.64 to 30.23; SUCRA = 99.2), followed by anti‐IL23 (versus placebo: RR 22.25, 95% CI 18.70 to 26.48; SUCRA = 86.4), anti‐IL12/23 (versus placebo: RR 17.71, 95% CI 14.68 to 21.36; SUCRA = 71.5), and anti‐TNF‐alpha (versus placebo: RR 13.33, 95% CI 11.21 to 15.85; SUCRA = 57.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab was superior to certolizumab (RR 1.43, 95% CI 1.07 to 1.92).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secukinumab, ixekizumab, brodalumab, risankizumab, and bimekizumab were more effective than ustekinumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adalimumab, tildrakizumab, and ustekinumab were superior to etanercept, deucravacitinib, and apremilast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For reaching PASI 90 at 52 weeks, risankizumab was more effective than ustekinumab (RR 1.73, 95% CI 1.46 to 2.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg | “69.7 (66.3-73.1)”View highlighted excerpt for this quote | “43.9 (40.2-47.9)”View highlighted excerpt for this quote | “16.7 (14.4-19.3)”View highlighted excerpt for this quote |
IL-17 inhibitors
Biologics guideline: recommendations for secukinumab, ixekizumab, and brodalumab, and inflammatory bowel disease
Secukinumab: FDA-approved indication, dosage, and week 12 outcomes in Trials PsO1 and PsO2
| Outcome at Week 12, Trial PsO1, n (%) | COSENTYX 300 mg (N = 245) | COSENTYX 150 mg (N = 245) | Placebo (N = 248) |
|---|---|---|---|
| PASI 75 response | “200 (82)” | “174 (71)” | “11 (4)” |
| IGA of clear or almost clear | “160 (65)” | “125 (51)” | “6 (2)” |
Ixekizumab: FDA-approved indication, dosage, and week 12 outcomes in Trial 1
| Outcome at Week 12, Trial 1, n (%) | TALTZ 80 mg Q2W (N=433) | Placebo (N=431) |
|---|---|---|
| sPGA of 0 (clear) or 1 (minimal) | “354 (82)” | “14 (3)” |
| PASI 90 | “307 (71)” | “2 (1)” |
| PASI 100 | “153 (35)” | “0” |
Brodalumab: boxed warning for suicidal ideation and behavior, REMS, restricted indication, and dosage
Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2
| Outcome at Week 12, Trial 2, n (%) | SILIQ 210 mg Q2W (N=612) | Ustekinumab (N=300) | Placebo (N=309) |
|---|---|---|---|
| PASI 75 response | “528 (86)” | “210 (70)” | “25 (8)” |
| PASI 100 response | “272 (44)” | “65 (22)” | “2 (1)” |
Bimekizumab: FDA-approved indication, dosage, suicidal ideation warning, and week 16 outcomes
| Outcome at Week 16, n (%) | Trial Ps-1 BIMZELX 320 mg every 4 weeks (N=321) | Trial Ps-1 placebo (N=83) | Trial Ps-2 BIMZELX 320 mg every 4 weeks (N=349) | Trial Ps-2 placebo (N=86) |
|---|---|---|---|---|
| IGA 0 or 1 | “270 (84%)” | “4 (5%)” | “323 (93%)” | “1 (1%)” |
| PASI 90 | “273 (85%)” | “4 (5%)” | “317 (91%)” | “1 (1%)” |
| PASI 100 | “188 (59%)” | “0 (0%)” | “238 (68%)” | “1 (1%)” |
BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis
“A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements: bimekizumab safety profile and candidiasis
“In the opinion of the guideline group, bimekizumab has, with the exception of candidiasis, a similar safety profile to other IL‐17 antagonists, such as ixekizumab and secukinumab, as well as the IL‐17R antagonist brodalumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infections: The three most common TEAEs were nasopharyngitis (19.1 per 100 person‐years; 95% CI 17.4–20.9 per 100 person‐years), oral candidiasis (12.6 per 100 person‐years; 95% CI 11.3–14.0 per 100 person‐years), and infections of the upper respiratory tract (8.9 per 100 person‐years; 95% CI 7.8–10.1 per 100 person‐years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dual inhibition of IL‐17A and IL‐17F may impair the protective function of mucous membranes more strongly, thus increasing the risk of oral candidiasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Decision aid: IL-17 inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Bimekizumab | “54%” | “Not known at present” |
| Brodalumab | “50%” | “Not known at present” |
| Ixekizumab | “53%” | “77–83% chance” |
| Secukinumab | “47%” | “80–83% chance” |
Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes
“In terms of reaching PASI 90, anti‐IL17 treatments (secukinumab, ixekizumab, izokibep, brodalumab, bimekizumab, sonelokimab, and xeligekimab) were more effective than placebo (class‐level RR 27.19, 95% CI 19.49 to 37.92).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At class level, anti‐IL17 treatment showed a higher proportion of participants reaching PASI 90 compared to all the interventions versus anti‐IL23 (RR 1.15, 95% CI 1.01 to 1.31); versus anti‐IL12/23 (RR 1.44, 95% CI 1.27 to 1.64); versus anti‐TNF‐alpha (RR 1.92, 95% CI 1.68 to 2.19); versus TYK‐2 inhibitors (RR 3.20, 95% CI 2.08 to 4.94); versus non‐targeted systemic treatments (RR 4.01, 95% CI 2.65 to 6.05); and versus phosphodiesterase‐4 inhibitors (RR 5.82, 95% CI 3.95 to 8.58) (Supplementary material 15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of a difference in favour of bimekizumab, ixekizumab, and risankizumab compared to secukinumab in terms of achieving PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Ixekizumab, 80 mg | “88.8 (86.5-90.9)”View highlighted excerpt for this quote | “70.8 (66.8-74.6)”View highlighted excerpt for this quote | “39.5 (35.2-44.0)”View highlighted excerpt for this quote |
| Brodalumab, 210 mg | “88.7 (86.5-90.8)”View highlighted excerpt for this quote | “70.6 (66.8-74.6)”View highlighted excerpt for this quote | “39.2 (35.2-43.9)”View highlighted excerpt for this quote |
| Secukinumab, 300 mg | “83.1 (80.2-85.7)”View highlighted excerpt for this quote | “61.4 (57.2-65.6)”View highlighted excerpt for this quote | “29.9 (26.3-33.9)”View highlighted excerpt for this quote |
IL-23 inhibitors
Biologics guideline: recommendations for guselkumab and tildrakizumab
Guselkumab: FDA-approved indication, dosage, and week 16 outcomes in Trials PsO1 and PsO2
| Outcome at Week 16, n (%) | Trial PsO1 placebo (N=174) | Trial PsO1 TREMFYA (N=329) | Trial PsO2 placebo (N=248) | Trial PsO2 TREMFYA (N=496) |
|---|---|---|---|---|
| IGA response of 0/1 | “12 (7)” | “280 (85)” | “21 (8)” | “417 (84)” |
| PASI 90 response | “5 (3)” | “241 (73)” | “6 (2)” | “347 (70)” |
Risankizumab: FDA-approved indication, dosage, and week 16 and week 52 outcomes in PsO-1 and PsO-2
| Outcome at Week 16, n (%) | PsO-1 SKYRIZI (N=304) | PsO-1 placebo (N=102) | PsO-2 SKYRIZI (N=294) | PsO-2 placebo (N=98) |
|---|---|---|---|---|
| sPGA 0 or 1 | “267 (88)” | “8 (8)” | “246 (84)” | “5 (5)” |
| PASI 90 | “229 (75)” | “5 (5)” | “220 (75)” | “2 (2)” |
| PASI 100 | “109 (36)” | “0 (0)” | “149 (51)” | “2 (2)” |
Tildrakizumab: FDA-approved indication, dosage, and week 12 outcomes in Trials 2 and 3
| Outcome at Week 12, n (%) | Trial 2 ILUMYA 100 mg (N=309) | Trial 2 placebo (N=154) | Trial 3 ILUMYA 100 mg (N=307) | Trial 3 placebo (N=156) |
|---|---|---|---|---|
| PGA of 0 or 1 | “179 (58)” | “11 (7)” | “168 (55)” | “7 (4)” |
| PASI 75 | “197 (64)” | “9 (6)” | “188 (61)” | “9 (6)” |
| PASI 90 | “107 (35)” | “4 (3)” | “119 (39)” | “2 (1)” |
Decision aid: IL-23 inhibitors
| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
|---|---|---|
| Guselkumab | “44%” | “85–90% chance” |
| Risankizumab | “51%” | “Not known at present” |
| Tildrakizumab | “32%” | “Not known at present” |
Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90
“Placebo had the highest SUCRA (SUCRA 93.9) at class‐level for all adverse events, followed by anti‐IL23 (versus placebo: RR 1.01, 95% CI 0.95 to 1.06; SUCRA = 89.9), anti‐TNF agents (versus placebo: RR 1.08, 95% CI 1.03 to 1.13; SUCRA = 61.3), and anti‐IL12/23 (versus placebo: RR 1.08, 95% CI 1.01 to 1.14; SUCRA = 60.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At class level, all treatment classes showed evidence of a higher risk of adverse events compared to placebo, except for anti‐IL23.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“guselkumab was more effective than adalimumab in reaching PASI 90 at 52 weeks (RR 1.59, 95% CI 1.40 to 1.81)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At weeks 44 to 60, the treatments with the highest PASI 90 rates were risankizumab-rzaa (79.4%, 95% CI, 75.5%-82.9%), guselkumab (76.5%; 95% CI, 72.1%-80.5%), brodalumab (74.0%; 95% CI, 69.3%-78.1%), and ixekizumab (73.9%; 95% CI, 69.9%-77.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
|---|---|---|---|
| Risankizumab-rzaa, 150 mg | “89.2 (86.9-91.3)”View highlighted excerpt for this quote | “71.6 (67.5-75.4)”View highlighted excerpt for this quote | “40.4 (35.9-45.0)”View highlighted excerpt for this quote |
| Guselkumab, 100 mg | “86.8 (83.8-89.4)”View highlighted excerpt for this quote | “67.3 (62.5-71.9)”View highlighted excerpt for this quote | “35.7 (30.9-40.7)”View highlighted excerpt for this quote |
| Tildrakizumab-asmn, 100 mg | “62.9 (57.3-68.4)”View highlighted excerpt for this quote | “36.8 (31.4-42.5)”View highlighted excerpt for this quote | “12.5 (9.7-15.8)”View highlighted excerpt for this quote |
Drug survival and switching risk with IL-23 inhibitors compared with other biologics
“Among 19,034 treatment courses (median follow‐up: 2.3 years), treatments included adalimumab (tumour necrosis factor‐alpha (TNF‐a) inhibitor, n = 6,815), ustekinumab (IL‐12/23p40 inhibitor, n = 5,639), secukinumab (IL‐17A inhibitor, n = 3,051), ixekizumab (IL‐17A inhibitor, n = 1,072), brodalumab (n = 367), guselkumab (IL‐23p19 inhibitor, n = 1,258) and risankizumab (n = 832).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guselkumab and risankizumab had the highest adjusted survival times (years [interquartile ranges]) for effectiveness (1.93 [1.91–1.95] and 1.93 [1.90–1.96], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months (p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: undertreatment, route of administration, persistence, and access
- Undertreatment: from 2003 through 2011, 23.6% to 35.5% of people with moderate psoriasis and 9.4% to 29.7% with severe psoriasis were untreated, 52.3% of those with psoriasis were dissatisfied with their treatment, and among those treated, 29.5% with moderate and 21.5% with severe psoriasis received topical agents alone. Of an estimated 1.7 million insured U.S. patients with moderate to severe psoriasis, 1 million (59%) were not treated in the preceding year, 807,000 had lapsed treatment, and 547,000 were treatment-naive; 40.9% were receiving therapy in the 12 months up to September 2012, and 22.5% of those treated received a biologic. In another study, more than 80% of psoriasis patients with ≥ 4 palms body surface area received no treatment or topical treatment only, and 45% had not seen a physician in a year.
- Route of administration: respondents in one preference study were willing to accept a reduction from approximately 70% to 40% in the proportion achieving clear or almost-clear skin to avoid injections at home and use a topical treatment. In a survey of 178 patient and 43 dermatologist respondents, both groups preferred oral to injectable treatments for moderate disease when attributes were held equal, and patients with higher needle fear were more likely to favor an oral treatment. Biologics are available only by injection or infusion. In the joint AAD-NPF phototherapy guideline, narrowband UVB is recommended 3 times weekly in the treatment phase, and travel to a phototherapy center can be a limiting factor.
- Persistence and switching: a meta-analysis of fifty-five studies estimated the proportions adherent and persistent to biological therapy at 0.61 (95% CI 0.48–0.73) and 0.63 (0.57–0.68), highest for ustekinumab and lowest for etanercept. Among 7997 biologic-treated people, switch rates were 14.4% at 12 months and 26.0% at 24 months; IL-23 inhibitors had the lowest risk of switching, with 8.5% for risankizumab and 15.7% for guselkumab over 24 months. The British Association of Dermatologists decision aid, drawing on UK real-world data, gives the likelihood of staying on treatment for more than 1 year as 67–73% for etanercept, 74–76% for adalimumab, 84–86% for ustekinumab, and 85–90% for guselkumab. Of 8,710 biologic-treated people, 11.5% switched and 31.1% discontinued, and switchers had higher adjusted total health care costs than nonswitchers (mean difference $10,120).
- Access: inability to obtain adequate insurance coverage was among the top reasons for discontinuing biological agents. Insurance plans in the USA often require patients to try and fail other treatments first (step therapy), a process that “often delays access to medically necessary treatments”. Several labels limit the indicated population: cyclosporine to severe, recalcitrant plaque psoriasis after failure of at least one systemic therapy or when other systemic therapies are contraindicated or not tolerated, brodalumab to patients who have failed to respond or lost response to other systemic therapies and only through a REMS program, and adalimumab and infliximab to patients for whom other systemic therapies are medically less appropriate.
Summary: efficacy of oral agents relative to biologics, safety warnings, and monitoring
- Efficacy in network meta-analyses: in a network meta-analysis of 204 studies with 67,889 randomized participants, anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF-alpha biologics showed a higher proportion of participants reaching PASI 90 than non-targeted and targeted systemic agents. At class level, the PASI 90 RR for anti-IL17 treatment was 3.20 versus TYK-2 inhibitors, 4.01 versus non-targeted systemic treatments, and 5.82 versus phosphodiesterase-4 inhibitors. Deucravacitinib and risankizumab were more effective than apremilast, and ciclosporin and methotrexate were superior to apremilast for PASI 90. A second network meta-analysis, of 60 trials, estimated PASI 90 at 10 to 16 weeks from baseline at 12.1% for apremilast and 11.4% for dimethyl fumarate, against 17.9% for etanercept, 43.7% for adalimumab, 43.9% for ustekinumab, 70.8% for ixekizumab, and 71.6% for risankizumab-rzaa. A review states that deucravacitinib was superior to apremilast and inferior to risankizumab.
- Limits of the comparative evidence: the network meta-analysis evidence is limited to induction therapy (outcomes from 8 to 24 weeks after randomisation), its participants had a mean age of 44.4 years and a baseline PASI of 20.5, and its serious adverse event analyses rested on a very low number of events. The guideline group of the EuroGuiDerm-adapted German S3 guideline stated it was not able to sufficiently differentiate recommendation levels for individual agents on PASI 90 and serious adverse events alone.
- Conventional oral agents: methotrexate achieved PASI 75 in 35.5% of patients against 79.6% with adalimumab, and acitretin 50 mg/d achieved PASI 75 in 23% after 8 weeks. Cyclosporine, methotrexate, and acitretin are described as having “limited efficacy and/or are associated with serious side effects and major monitoring requirements”.
- Safety warnings: the labels of adalimumab, etanercept, infliximab, and certolizumab pegol state an increased risk of serious infections that may lead to hospitalization or death, and the adalimumab label reports lymphoma and other malignancies in children and adolescents treated with TNF blockers. The JYLAMVO (methotrexate) label reports serious adverse reactions including death, and hepatotoxicity risk that generally occurs after a cumulative dose of 1.5 g or more. Cyclosporine can cause hypertension and nephrotoxicity (cyclosporine nephropathy in 18/86 [21%] of biopsied psoriasis patients). Acitretin must not be used by females who are pregnant or intend to become pregnant during therapy or for at least 3 years after discontinuation. Suicidal ideation and behavior, including completed suicides, have occurred with brodalumab, and bimekizumab carries a warning for suicidal ideation and behavior; oral candidiasis occurred in 19.3% with bimekizumab and 3.0% with secukinumab. The AAD-NPF biologics guideline recommends avoiding IL-17 inhibitors in patients with a personal history of or active IBD. With apremilast, depression was reported in 1.3% vs. 0.4% with placebo and weight decrease of 5%-10% in 12% vs. 5%, and diarrhea and nausea each occurred in 17%. The deucravacitinib label warns of infections, CPK elevation and rhabdomyolysis, and triglyceride elevations, and a review describes deucravacitinib as the only JAK or TYK2 inhibitor indicated for psoriasis that “does not have a boxed warning”. Class 1 topical corticosteroids are limited to up to 4 weeks, and tachyphylaxis may occur with use beyond 12 weeks.
- Screening and monitoring: deucravacitinib requires evaluation for active and latent tuberculosis before treatment and periodic evaluation of serum triglycerides; for icotrokinra, tuberculosis evaluation is considered based on clinical judgement and live vaccines are avoided. The adalimumab label directs monitoring of all patients for active tuberculosis during treatment, even if the initial latent test is negative; cyclosporine requires frequent monitoring of serum creatinine; the EuroGuiDerm-adapted guideline group monitors methotrexate with transaminases; and periodic assessment of suicidal ideation is recommended with brodalumab. Apremilast has no requirement for laboratory monitoring.
Untreated and undertreated psoriasis and treatment dissatisfaction, 2003 to 2011
“From 2003 through 2011, patients who were untreated ranged from 36.6% to 49.2% of patients with mild psoriasis, 23.6% to 35.5% of patients with moderate psoriasis, and 9.4% to 29.7% of patients with severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 52.3% of patients with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Untreated, lapsed, and switched treatment among insured U.S. patients with moderate to severe psoriasis
“There were an estimated 1.7 million insured US patients with moderate to severe psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 1 million (59%) were not treated for their condition in the preceding year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, an estimated 807,000 patients had lapsed treatment, an additional 346,000 were receiving treatment, and 547,000 were defined as being treatment-naive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 81,000 of 346,000 patients had switched treatment in the preceding year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insurance coverage and step therapy as barriers to biologic treatment
“Although adverse effects and a lack of effectiveness were primary reasons for discontinuing biological agents, the inability to obtain adequate insurance coverage was among the top reasons for discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This process often delays access to medically necessary treatments, with patients’ conditions potentially worsening each day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injection burden and preference for oral administration
“For example, respondents were willing to accept a reduction in the percentage of patients who achieve clear or almost-clear skin after treatment from approximately 70% to 40% to avoid injections at home and use a topical treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Topical treatments were the most preferred option of administration followed by oral agents and intravenous infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Completed surveys from 178 patients and 43 dermatologists were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence and persistence to biologics: meta-analysis
“Sixty-two records met the inclusion criteria, and a meta-analysis was conducted on fifty-five studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the proportion of adherent and persistent patients to biological therapy was 0.61 (95% confidence interval: 0.48–0.73) and 0.63 (0.57–0.68), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest proportions were found for ustekinumab, while the lowest ones were found for etanercept.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biologic switch rates at 12 and 24 months and predictors of switching
“A total of 7997 patients were included, with overall treatment switch rates at 14.4% at 12 months and 26.0% at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prior targeted immune modulator use, age, and female gender were predictors of switching (adjusted hazard ratio; 1.23, 1.31, and 1.40, respectively; p ≤ 0.0005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy gap of oral agents relative to biologics: network meta-analysis
“Biologic treatments anti‐IL17, anti‐IL12/23, anti‐IL23, and anti‐tumour necrosis factor (TNF)‐alpha showed a higher proportion of participants reaching PASI 90 than the non‐targeted systemic agents and the targeted systemic agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis evidence limited to induction-phase outcomes and trial populations
“This update includes 26 new studies, taking the total number of included studies to 204, and randomised participants to 67,889 (67% men), mainly recruited from hospitals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This network meta‐analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer‐term outcomes in this chronic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, the SAEs analyses were based on a very low number of events with low‐certainty evidence for most comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the results of the network comparisons for the outcome measures PASI 90 and SAE alone, the guideline group is not able to sufficiently differentiate the recommendation levels for the individual agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: severity definitions and candidacy for systemic therapy
- The German S3 guideline adapted from EuroGuiDerm (Nast et al.) defines mild psoriasis as “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” and moderate to severe psoriasis as “(BSA > 10 or PASI > 10) and DLQI > 10”. Mild disease is upgraded to moderate-to-severe by major involvement of visible areas or the scalp, involvement of the genitals, palms, or soles, onycholysis or onychodystrophy of at least two fingernails, pruritus leading to scratching, or recalcitrant plaques. Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15, rapid deterioration, and severe involvement of the hands and/or feet, scalp, face, nails, or genitals.
- The most preferred statement reported by Strober et al. classifies patients as candidates for topical therapy or candidates for systemic therapy; the latter meet at least one of three criteria: body surface area >10%, disease involving special areas, or failure of topical therapy.
- The National Psoriasis Foundation classifies a patient as having mild psoriasis, managed with topical therapies, or moderate-to-severe psoriasis, which makes the patient a candidate for advanced therapies, including phototherapy and modern systemic treatments; it states that current systemic treatments include oral and biologic therapies.
- The deucravacitinib label indicates it for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the icotrokinra label for the same population and for pediatric patients 12 years of age and older who weigh at least 40 kg, and the apremilast label for adults with plaque psoriasis who are candidates for phototherapy or systemic therapy. Trials PSO-1 and PSO-2 of the icotrokinra label defined moderate-to-severe plaque psoriasis as IGA score ≥3, PASI score ≥12, and BSA involvement ≥10%.
Summary: guideline positions on first systemic therapy and oral agents
- EuroGuiDerm-adapted German S3 guideline (Nast et al.): when systemic treatment is initiated for the first time, the guideline suggests a biologic with a first-line label or deucravacitinib, especially for psoriasis of particular severity. It bases this on the disease burden of particularly severe psoriasis and on the results of the Cochrane review, and its classification of first-line and second-line agents follows the approved indications in the summary of product characteristics.
- In the EuroGuiDerm-adapted guideline's summary of the Cochrane network meta-analysis (Nast et al.), infliximab, the anti-IL-17 drugs, and the anti-IL-23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti-TNF alpha agents, and deucravacitinib, and no significant difference was shown between apremilast and ciclosporin or methotrexate. Sbidian et al. state that deucravacitinib and risankizumab were more effective than apremilast and that ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.
- AAD-NPF guideline on systemic nonbiologic therapies (Menter et al.): the guideline states that apremilast “is recommended for the treatment of moderate to severe psoriasis in adults” and describes it as an appropriate choice for patients who prefer to avoid frequent injections and laboratory monitoring and are willing to accept a slower onset of skin clearance and a lower likelihood of clearing. It also recommends methotrexate for moderate to severe psoriasis in adults and cyclosporine for severe, recalcitrant psoriasis.
- Preference for oral therapy: among 397 respondents, avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy. The Alumis corporate presentation states “75% Patients prefer orals over injectables”.
Summary: oral agents, head-to-head evidence, and the comparative evidence for envudeucitinib
- Oral agents with a U.S. label: deucravacitinib 6 mg once daily; apremilast 30 mg twice daily after a 5-day titration, or the extended-release tablet 75 mg once daily; and icotrokinra 200 mg once daily upon waking on an empty stomach, whose market introduction date is 2026-03-18 in the California HCAI new prescription drugs file. The FDA accepted the zasocitinib NDA under Priority Review, with a PDUFA target action date in the first quarter of calendar year 2027.
- Deucravacitinib versus apremilast: at week 16, PASI 75 was achieved by 58.4% with deucravacitinib, 35.1% with apremilast, and 12.7% with placebo in POETYK PSO-1, and by 53.0%, 39.8%, and 9.4% in POETYK PSO-2.
- Icotrokinra versus deucravacitinib: in Trial PSO-1 of the icotrokinra label, week 16 PASI 90 was achieved by 171 of 311 (55%) icotrokinra and 91 of 307 (30%) deucravacitinib participants and PASI 100 by 97 (31%) and 34 (11%); in Trial PSO-2, week 16 PASI 90 was achieved by 184 (58%) and 111 (34%), while Stein Gold et al. report 184 of 322 (57%) for icotrokinra in ADVANCE 2. Through week 24 of ICONIC-ADVANCE 1 and 2, adverse events occurred in 359 of 632 (57%) icotrokinra and 411 of 634 (65%) deucravacitinib participants.
- Zasocitinib: against deucravacitinib in LATITUDE Atlas (606 participants), week 16 PASI 100 was 36.5% (n=301) and 13.9% (n=303) and PASI 90 was 62.5% and 34.0%. Against apremilast at week 16, PASI 75 was 76% and 37% in LATITUDE PsO 3001 and 71% and 33% in LATITUDE PsO 3002 (Takeda press releases).
- Oral agent versus biologic: in the open-label IMMpactful trial, funded by AbbVie, PASI 90 at week 16 was achieved by 57.3% with risankizumab and 22.9% with deucravacitinib.
- Envudeucitinib: ONWARD1 and ONWARD2 compared envudeucitinib with placebo and apremilast, and STRIDE compared five envudeucitinib doses with placebo. The report holds no head-to-head trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”, and De Luca et al. state that the next-generation agents have been compared with placebo, apremilast, or deucravacitinib and have not been compared with IL-17 or IL-23 inhibitors. The Alumis corporate presentation compares PASI 100 rates of envudeucitinib (ONWARD1 and ONWARD2 at week 24), icotrokinra, and zasocitinib across trials and states that the results of this “retrospective post hoc cross-trial comparison may not be directly comparable”.
- Care setting: Alumis states that its success will depend upon physicians specializing in the treatment of the targeted diseases prescribing its product candidates. A single-center retrospective review drew on referrals for specialty medications by dermatology providers for psoriasis or atopic dermatitis and on the specialty pharmacy patient management system. In the United States, access to dermatologists “is limited in many regions”, especially in underserved and rural communities.
Guideline recommendation for the first systemic therapy: a biologic with a first-line label or deucravacitinib
“If systemic treatment of psoriasis is initiated for the first time, we suggest treatment with a biologic with first‐line label or with deucravacitinib, especially for psoriasis of particular severity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend initiating a systemic treatment in patients with moderate to severe psoriasis according to Figure 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the guideline's first systemic therapy recommendation and first-line classification
“The recommendation IX‐3 on the direct use of first‐line biologics or deucravacitinib is justified by the particularly high disease burden in particularly severe psoriasis and based on the results of the Cochrane review” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The classification of agents in 1st line and 2nd line, as presented in Figure 3, was based on the approved indications listed in the summary of product characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PASI 90 likelihood with biologics, deucravacitinib, and apremilast in the guideline summary of the Cochrane network meta-analysis
“Infliximab, anti‐IL‐17 drugs (bimekizumab, ixekizumab, secukinumab, and brodalumab), and anti‐IL‐23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti‐TNF alpha agents, and deucravacitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant difference was shown between apremilast and two non‐biologic drugs: ciclosporin and MTX.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
National Psoriasis Foundation position on severity and candidacy for oral and biologic systemic therapies
Patient preference for oral or topical administration over injections: 397 respondents
“A total of 397 respondents, with a mean self-assessed Psoriasis Activity and Severity Index score of 8.2 (SD, 9.8), provided data for analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The maximum possible improvement in treatment efficacy offered in the study was not enough to match the improvements in well being associated with some changes in mode of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigator statement on the choice between oral and biologic therapies
Manufacturer statements on the intended position of envudeucitinib among oral therapies
Prescribing specialists and uptake: manufacturer statement
Care setting: dermatology referral and specialty pharmacy dispensing of targeted therapies
“A single-center, retrospective review of data collected from electronic health records and the specialty pharmacy patient management system was conducted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were included if they had a referral for a specialty medication by a dermatology provider for PsO or AD that was discontinued because of the payer/PBM requiring step therapy or formulary alternative use from January 2021 to June 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included 24,767 patients (535 HCPro; 24,232 non-HCPro).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HCPro patients had a greater frequency of initiation at a specialty pharmacy (66% vs. 56%; P < 0.001) and enrollment in AbbVie’s patient support program (71% vs. 51%; P < 0.001) as well as a lower copay for ADA ($206 vs. $265; P = 0.011).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access to dermatologists in underserved and rural communities
“In the United States, access to dermatologists is limited in many regions, and this lack of access is especially pronounced among patients in underserved and rural communities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Telemedicine has the potential to allow for collaborative connected-health models to expand the reach of experienced dermatologists to help comanage patients with primary care physicians and community dermatologists who are not comfortable with newer systemic treatments for psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
German S3 guideline adapted from the EuroGuiDerm guideline, part 1: scope and approval
“This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The authors of this work have adapted, remixed, transformed, translated or built upon a previous version of the following article: EUROGUIDERM GUIDELINE FOR THE SYSTEMIC TREATMENT OF PSORIASIS by Nast A et al.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present adapted guideline did not undergo an approval procedure by the European Dermatology Forum, but has been approved by the editing German societies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Guideline recommendation to select systemic therapy by comorbidity and individual patient factors
“We recommend taking into account efficacy (see Figure 1, Figure 2, and summary of the Cochrane Review), safety (see drug chapters), comorbidities (see Table 1 and Table 2 in publication Part 2, and respective chapters in the long version), and individual patient factors when choosing a systemic treatment for moderate to severe psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accordingly, individual recommendation strengths arise individually from the examination of each patient, taking the factors effectiveness, safety, comorbidity, and other individual patient factors into account.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis
“In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with latent TB infection, we recommend choosing one of the following options:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against the use of deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in patients with latent TB infections unless there are no other suitable treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Conditions that make a biologic class less suitable: decision aid
| Biologic class | Conditions listed in the decision aid |
|---|---|
| TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab) | “Moderate or severe heart failure, multiple sclerosis (or other conditions affecting the nerves)” |
| IL-12/23 inhibitor (ustekinumab) | “No particular condition” |
| IL-17 inhibitors (bimekizumab, brodalumab, ixekizumab, secukinumab) | “Inflammatory bowel disease (e.g. Crohn disease or ulcerative colitis), recurrent candida infection (i.e. thrush)” |
Agent selection by comorbidity, special population, and phenotype: U.S. reviews
“Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Choosing systemic therapy for psoriasis remains challenging in populations underrepresented in clinical trials, including pregnant and pediatric patients, patients with chronic infections, and those with difficult-to-treat phenotypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Emphasis is placed on balancing efficacy, safety, monitoring burden, infection/reactivation risk, reproductive considerations, and disease phenotype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: overweight and early loss of biologic efficacy in severe psoriasis
“Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: exposure and dosing statements in biologic labels
Response across age, sex, race, body weight, baseline severity, and prior therapy subgroups: oral agent labels
Response across age, sex, race, body weight, and prior therapy subgroups: IL-17 and IL-23 inhibitor labels
Bimekizumab PASI 100 through 3 years by age, sex, weight, disease duration, severity, nail involvement, and prior biologic exposure
“Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]–73.7% [≥ 65 years]), sex (69.6% [male]–71.4% [female]), weight (63.4% [≥ 103.9 kg]–75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]–71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]–71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks
“Among the total 110 patients, 71 were apremilast‐naïve and 39 were apremilast‐experienced, while 95 were biologic‐naive and 15 were biologic‐experienced (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both in biologic naive and experienced patients, mean PASI scores continued to decrease from week 0 to week 52; however, the magnitude of decrease appeared higher in biologic‐naive patients: from 15.53 to 1.30 in biologic‐naive patients (91.6% reduction) versus from 7.78 to 3.30 (57.6% reduction) in biologic‐experienced patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We studied 131 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg/day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Week 104 achieving PASI 100 and absolute PASI ≤ 1 were higher in apremilast-naïve patients (15.4% and 53.8%) than in apremilast-experienced patients (0% and 25%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Week 104 achieving PASI 75, PASI 90, PASI 100, and absolute PASI ≤ 1 were higher in biologic-naïve patients (84.6%, 57.7%, 15.4%, and 53.8%) than in biologic-experienced patients (25%, 25%, 0%, and 25%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior apremilast nonresponse: deucravacitinib response in POETYK PSO-1 and PSO-2 through week 52
“Of 168 (PSO-1) and 254 (PSO-2) patients randomized to apremilast, 54 (32.1% [PSO-1]) and 111 (43.7% [PSO-2]) did not achieve PASI 50 (PSO-1) and PASI 75 (PSO-2) at Week 24 and were switched to deucravacitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PASI 75 response rates improved from 0% at Week 24 to 46.3% (PSO-1) and 42.3% (PSO-2) at Week 52.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior systemic treatment status and the network meta-analysis
“Indeed, response to biologics is different depending on treatment status (systemic‐naïve or not).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, due to the limited number of studies available for some specific comparisons, subgroup analyses and meta‐regressions were not possible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Asian populations: deucravacitinib network meta-analysis estimates
“Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated PASI 75 and 90 (95% credible interval) response rates for deucravacitinib were estimated to be 66% (49%–80%) and 40% (24%–58%) in Asian populations, notably higher than placebo (6% [4%–9%] and 1% [0.8–2%]) and apremilast (24% [12%–40%] and 9% [4%–20%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No statistically significant difference was observed in PASI 75 and 90 responses between deucravacitinib and adalimumab, certolizumab pegol, infliximab, ustekinumab, and tildrakizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Japanese participants in POETYK PSO-1: week 16 and week 24 PASI 75
“This report describes efficacy and safety in Japanese patients from this study (N = 66) who were randomly assigned to treatment with deucravacitinib 6 mg once daily (n = 32), placebo (n = 17), or apremilast 30 mg twice daily (n = 17).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of Japanese patients achieving ≥75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% vs. 29.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy and safety of deucravacitinib in Japanese patients was consistent with those in the global population in POETYK PSO-1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified efficacy and safety subgroups in the envudeucitinib phase 2 statistical analysis plan
“BSA involvement (10–20 %, > 20 %)” (opens the source at this quote in a new tab)
“PASI (≤ 20, > 20)” (opens the source at this quote in a new tab)
“Race (White, Non-white)” (opens the source at this quote in a new tab)
“Baseline weight category (<90 kg, ≥ 90 kg)” (opens the source at this quote in a new tab)
“Baseline BMI category (<30 kg/m2, ≥30 kg/ m2)” (opens the source at this quote in a new tab)
“Prior use of biologics (yes, no)” (opens the source at this quote in a new tab)
“Prior use of TYK 2 molecules (yes, no)” (opens the source at this quote in a new tab)
Care management intervention strategies
Treat-to-target strategy: National Psoriasis Foundation Delphi consensus on instrument and evaluation timing
“The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 25 psoriasis experts participated in the Delphi process.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most preferred instrument was body surface area (BSA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most preferred time for evaluating patient response after starting new therapies was at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the maintenance period, evaluation every 6 months was most preferred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment goal monitoring and therapy modification: guideline
“Various forms of adjustment include increasing the dosage, initiation of combination therapy, or transitioning to another drug or procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment goals must be determined individually with the patients in a joint decision‐making process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During maintenance therapy, control of treatment goals should be done at the same intervals as the general monitoring, usually every 8 to 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tuberculosis screening before and during biologic or deucravacitinib therapy: guideline
“A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend excluding latent TB infection using interferon‐gamma release assay (IGRA) before initiating treatment with a biologic agent or deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib: due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against repeating IGRA just based on fixed time intervals or due to switching from one drug to another without relevant risk of exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend repeating IGRA during treatment if there is an increased risk of TB exposure (see background text: Indications for an increased probability of an exposure risk).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Latent tuberculosis testing for IL-17 and IL-23 inhibitors: NPF and IPC joint position
“Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tuberculosis testing requirement removed for risankizumab and absent for icotrokinra
Hepatitis B and hepatitis C screening before systemic therapy: guideline
“We recommend screening patients for hepatitis B (HBsAg, anti‐HBs, anti‐HBc) as a routine measure before starting a treatment with ciclosporin, deucravacitinib, methotrexate, or biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest screening patients for hepatitis C as a routine measure before starting a treatment with deucravacitinib, methotrexate, or biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against screening for hepatitis A, D, or E as a routine measure before starting a systemic treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If viral hepatitis has been excluded once before initiating an immunosuppressive therapy and there is no history‐related/laboratory evidence of infection, re‐testing is not required when changing the therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pretreatment workup for deucravacitinib: guideline expert recommendations
“Check need for vaccinations according to current vaccination recommendations including prophylactic vaccination against herpes zoster” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform patients to discontinue treatment and present for examination if they experience muscle weakness or pain, especially if these are accompanied by fatigue or fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Not all tests may be required for all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommendations are based on expert opinions and take into account that the experience with the drug is still limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination timing and live vaccines during oral and biologic therapy
“The optimal time for vaccinations is before starting a systemic immunosuppressive therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, inactivated vaccines can be used safely in patients receiving systemic immunosuppressive therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity screening: psoriatic arthritis at each visit and cardiovascular risk assessment
Telemedicine management of psoriasis
“Telemedicine utilization among dermatologists increased from under 15% to >95% after the pandemic, reflecting its marked popularity among patients and uptake for physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with in-person care, collaborative and efficient teledermatology models equivalently improve PASI scores, BSA, and dermatology life quality index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Teledermatology is a reasonable alternative for providing long-term management of patients with psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to guarantee the accessibility of in-person care for patients with psoriasis and ensure that telemedicine does not supplant such availability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PEST should be provided to patients every 6 months to screen for PsA to help mitigate the undertreatment and delay in the diagnosis of this common comorbidity in patients with psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Online and in-person care: 12-month randomized equivalency trial in 296 adults
“Overall, 296 adults with physician-diagnosed psoriasis from ambulatory clinics were randomly assigned to either online or in-person care; all were analyzed for outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across 12 months, for the online group, the mean ± standard deviation decline in Skindex-16 from baseline across follow-up visits was 9.02 ± 20.67 compared with 10.55 ± 23.50 for the in-person group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over the 12-month study period, the in-person group had a total of 315 in-person visits; the online group had 161 online visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Shared decision-making aid for biologic choice: dosing interval by agent
| Agent | How often do I need to inject the treatment? |
|---|---|
| Adalimumab | “Every other week” |
| Certolizumab pegol | “Every 2 weeks” |
| Etanercept | “Once or twice a week” |
| Infliximab | “Every 8 weeks” |
| Ustekinumab | “Every 12 weeks” |
| Bimekizumab | “Every 8 weeks” |
| Brodalumab | “Every 2 weeks” |
| Ixekizumab | “Every 4 weeks” |
| Secukinumab | “Every month” |
| Guselkumab | “Every 8 weeks” |
| Risankizumab | “Every 12 weeks” |
| Tildrakizumab | “Every 12 weeks” |
Pharmacy-led prior authorization management in dermatology
“Biologic agents (55.2%) and brand-name only medications (42.8%) required PA at higher rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacy intervention resulted in shorter time to PA submission (4 days vs 1 day, P < .001) and decision (6 days vs 1 day, P < .001) and higher approval rates (63.9% vs 80.6%, P < .001) but did not decrease the total number of PAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with approved PAs had higher likelihood of disease improvement vs those with denied PAs (71.1% vs 58.0%, P = .013).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Online prescription management and specialty pharmacy support: abandonment and time to first fill
“HCPro patients had a lower abandonment rate (6.4% vs. 13.9%; P < 0.001) and reduced days to prescription fill (7.0 vs. 14.4; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After controlling for baseline characteristics, abandonment odds were 43% lower for patients using HCPro (odds ratio = 0.57; P = 0.004).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence interventions including pharmacist-delivered models: systematic review of 26 studies
“Twenty-six studies were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Digital and technology‐supported interventions, including mobile applications, short message service reminders and electronic monitoring‐supported platforms were the most frequently evaluated and were generally associated with modest improvements in adherence when compared to usual care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare professional‐led interventions such as nurse and pharmacist delivered models demonstrated potential benefits in adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across studies, improvements in adherence were more consistently observed than improvements in clinical severity and quality‐of‐life outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Step therapy before specialty medication: time to second referral in psoriasis and atopic dermatitis
“The included patients (N = 83) were predominantly White (75%) and female (61%) with a median age of 50 years (interquartile range [IQR] = 37-61 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“62 patients were required to use step therapy, and 21 were required to use a formulary alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients required to use step therapy, 37 (60%) had a second referral for a specialty medication because of failing step therapy requirements, with a median time to a second referral of 75 days (IQR = 27-135).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior authorization burden, approval rates, and wait times for biologics
“In September 2016, 626 PAs were generated from 9512 patient encounters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Records from the University of Miami Health System were reviewed, and 101 patients were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with Medicare had the shortest wait time with a mean of 7.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Private insurance patients waited the longest, regardless of whether they had a PPO (37 days) or HMO (41.3 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
German S3 guideline adapted from EuroGuiDerm, part 2: specific clinical and comorbid situations
“S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
British Association of Dermatologists guideline for biologic therapy: living guideline transition, decision aid update, and dosing question
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
- Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
- Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
- Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
- Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
- Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.
Guideline treatment goals: PASI 75 minimum and PASI 90, absolute PASI below 2, or DLQI of 1 or less as the desired goal
“The fundamental goal of any therapy is to achieve complete clearance of symptoms – that is, the absence of cutaneous symptoms of psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, this goal is not realistically achievable in all patients at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the end of the induction period, a PASI 75 response is the minimum target, which should be controlled for at regular intervals during the course of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reaching a PASI 90 response or an absolute PASI <2 or DLQI ≤ 1 should be the desired treatment goal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-to-target response thresholds: BSA of 1% or less at 3 months and every 6 months
“The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The target response at 3 months postinitiation was BSA 1% or less.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The target response at every 6 months maintenance evaluation is BSA 1% or less.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to response and timing of the treatment goal assessment
“For treatments with a fast onset of action, treatment goals should be controlled for at the end of the induction therapy after 10 to 12 weeks; for treatments with a slower onset of action, this should be done after 16 to 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These time frames may not always include the time of maximum therapeutic effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-five trials were included in the main analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and symptom resolution at PASI 90, PASI 95, and PASI 100
“Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability with continuous risankizumab through week 304
“Of 897 patients enrolled in the LIMMitless study, 661 completed the study for a total of 4921.2 patient years of exposure to risankizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 304, 86.0% of patients achieved PASI 90, 54.2% achieved PASI 100, 84.7% achieved sPGA 0/1, and 76.3% achieved DLQI 0/1 (using modified nonresponder imputation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability with continuous secukinumab 300 mg through year 5
“At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote